#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-3	The	_
1-2	4-6	P1	_
1-3	7-20	Visual-Evoked	_
1-4	21-30	Potential	_
1-5	31-32	,	_
1-6	33-36	Red	_
1-7	37-42	Light	_
1-8	43-44	,	_
1-9	45-48	and	_
1-10	49-64	Transdiagnostic	_
1-11	65-76	Psychiatric	_
1-12	77-85	Symptoms	_
1-13	86-87	A	_
1-14	88-95	reduced	_
1-15	96-98	P1	_
1-16	99-112	visual-evoked	_
1-17	113-122	potential	_
1-18	123-132	amplitude	_
1-19	133-136	has	_
1-20	137-141	been	_
1-21	142-150	reported	_
1-22	151-157	across	_
1-23	158-165	several	_
1-24	166-177	psychiatric	_
1-25	178-187	disorders	_
1-26	188-189	,	_
1-27	190-199	including	_
1-28	200-222	schizophrenia-spectrum	_
1-29	223-224	,	_
1-30	225-232	bipolar	_
1-31	233-234	,	_
1-32	235-238	and	_
1-33	239-249	depressive	_
1-34	250-259	disorders	_
1-35	260-261	.	_

2-1	262-264	In	_
2-2	265-273	addition	_
2-3	274-275	,	_
2-4	276-277	a	_
2-5	278-288	difference	_
2-6	289-291	in	_
2-7	292-294	P1	_
2-8	295-304	amplitude	_
2-9	305-311	change	_
2-10	312-314	to	_
2-11	315-316	a	_
2-12	317-320	red	_
2-13	321-331	background	_
2-14	332-340	compared	_
2-15	341-343	to	_
2-16	344-347	its	_
2-17	348-356	opponent	_
2-18	357-362	color	_
2-19	363-364	,	_
2-20	365-370	green	_
2-21	371-372	,	_
2-22	373-376	has	_
2-23	377-381	been	_
2-24	382-387	found	_
2-25	388-390	in	_
2-26	391-413	schizophrenia-spectrum	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
2-27	414-421	samples	_
2-28	422-423	.	_

3-1	424-427	The	_
3-2	428-435	current	_
3-3	436-441	study	_
3-4	442-450	examined	_
3-5	451-458	whether	_
3-6	459-467	specific	_
3-7	468-479	psychiatric	_
3-8	480-488	symptoms	_
3-9	489-493	that	_
3-10	494-501	related	_
3-11	502-504	to	_
3-12	505-510	these	_
3-13	511-513	P1	_
3-14	514-527	abnormalities	_
3-15	528-530	in	_
3-16	531-538	earlier	_
3-17	539-546	studies	_
3-18	547-552	would	_
3-19	553-555	be	_
3-20	556-566	replicated	_
3-21	567-571	when	_
3-22	572-577	using	_
3-23	578-579	a	_
3-24	580-585	broad	_
3-25	586-601	transdiagnostic	_
3-26	602-608	sample	_
3-27	609-610	.	_

4-1	611-614	The	_
4-2	615-620	final	_
4-3	621-627	sample	_
4-4	628-637	consisted	_
4-5	638-640	of	_
4-6	641-644	135	_
4-7	645-657	participants	_
4-8	658-659	:	_
4-9	660-662	26	_
4-10	663-667	with	_
4-11	668-675	bipolar	_
4-12	676-685	disorders	http://maven.renci.org/NeuroBridge/neurobridge#ExtrapyramidalDisease
4-13	686-687	,	_
4-14	688-690	25	_
4-15	691-695	with	_
4-16	696-718	schizophrenia-spectrum	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
4-17	719-728	disorders	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
4-18	729-730	,	_
4-19	731-733	19	_
4-20	734-738	with	_
4-21	739-747	unipolar	_
4-22	748-758	depression	_
4-23	759-760	,	_
4-24	761-763	62	_
4-25	764-768	with	_
4-26	769-771	no	_
4-27	772-779	current	_
4-28	780-791	psychiatric	_
4-29	792-800	disorder	_
4-30	801-802	,	_
4-31	803-806	and	_
4-32	807-808	3	_
4-33	809-813	with	_
4-34	814-823	disorders	_
4-35	824-826	in	_
4-36	827-832	other	_
4-37	833-843	categories	_
4-38	844-845	.	_

5-1	846-849	Low	_
5-2	850-851	(	_
5-3	852-853	8	_
5-4	854-855	%	_
5-5	856-857	)	_
5-6	858-861	and	_
5-7	862-866	high	_
5-8	867-868	(	_
5-9	869-871	64	_
5-10	872-873	%	_
5-11	874-875	)	_
5-12	876-884	contrast	_
5-13	885-890	check	_
5-14	891-897	arrays	_
5-15	898-902	were	_
5-16	903-912	presented	_
5-17	913-915	on	_
5-18	916-920	gray	_
5-19	921-922	,	_
5-20	923-928	green	_
5-21	929-930	,	_
5-22	931-934	and	_
5-23	935-938	red	_
5-24	939-949	background	_
5-25	950-960	conditions	_
5-26	961-967	during	_
5-27	968-988	electroencephalogram	_
5-28	989-990	,	_
5-29	991-996	while	_
5-30	997-999	an	_
5-31	1000-1003	eye	_
5-32	1004-1011	tracker	_
5-33	1012-1021	monitored	_
5-34	1022-1028	visual	_
5-35	1029-1037	fixation	_
5-36	1038-1040	on	_
5-37	1041-1044	the	_
5-38	1045-1052	stimuli	_
5-39	1053-1054	.	_

6-1	1055-1061	Linear	_
6-2	1062-1073	regressions	_
6-3	1074-1080	across	_
6-4	1081-1084	the	_
6-5	1085-1091	entire	_
6-6	1092-1098	sample	_
6-7	1099-1100	(	_
6-8	1101-1102	N	_
6-9	1103-1104	=	_
6-10	1105-1108	135	_
6-11	1109-1110	)	_
6-12	1111-1116	found	_
6-13	1117-1121	that	_
6-14	1122-1129	greater	_
6-15	1130-1138	severity	_
6-16	1139-1141	of	_
6-17	1142-1146	both	_
6-18	1147-1162	clinician-rated	_
6-19	1163-1166	and	_
6-20	1167-1180	self-reported	_
6-21	1181-1198	delusions/magical	_
6-22	1199-1207	thinking	_
6-23	1208-1218	correlated	_
6-24	1219-1223	with	_
6-25	1224-1225	a	_
6-26	1226-1233	reduced	_
6-27	1234-1236	P1	_
6-28	1237-1246	amplitude	_
6-29	1247-1249	on	_
6-30	1250-1253	the	_
6-31	1254-1257	low	_
6-32	1258-1266	contrast	_
6-33	1267-1271	gray	_
6-34	1272-1273	(	_
6-35	1274-1281	neutral	_
6-36	1282-1283	)	_
6-37	1284-1294	background	_
6-38	1295-1304	condition	_
6-39	1305-1306	.	_

7-1	1307-1309	In	_
7-2	1310-1318	addition	_
7-3	1319-1320	,	_
7-4	1321-1327	across	_
7-5	1328-1331	the	_
7-6	1332-1338	entire	_
7-7	1339-1345	sample	_
7-8	1346-1347	,	_
7-9	1348-1354	higher	_
7-10	1355-1368	self-reported	_
7-11	1369-1380	constricted	_
7-12	1381-1387	affect	_
7-13	1388-1391	was	_
7-14	1392-1402	associated	_
7-15	1403-1407	with	_
7-16	1408-1409	a	_
7-17	1410-1416	larger	_
7-18	1417-1425	decrease	_
7-19	1426-1428	in	_
7-20	1429-1431	P1	_
7-21	1432-1441	amplitude	_
7-22	1442-1443	(	_
7-23	1444-1452	averaged	_
7-24	1453-1459	across	_
7-25	1460-1468	contrast	_
7-26	1469-1479	conditions	_
7-27	1480-1481	)	_
7-28	1482-1484	to	_
7-29	1485-1488	the	_
7-30	1489-1492	red	_
7-31	1493-1494	,	_
7-32	1495-1503	compared	_
7-33	1504-1506	to	_
7-34	1507-1512	green	_
7-35	1513-1514	,	_
7-36	1515-1525	background	_
7-37	1526-1527	.	_

8-1	1528-1531	All	_
8-2	1532-1545	relationships	_
8-3	1546-1554	remained	_
8-4	1555-1568	statistically	_
8-5	1569-1580	significant	_
8-6	1581-1586	after	_
8-7	1587-1596	covarying	_
8-8	1597-1600	for	_
8-9	1601-1611	diagnostic	_
8-10	1612-1617	class	_
8-11	1618-1619	,	_
8-12	1620-1630	suggesting	_
8-13	1631-1635	that	_
8-14	1636-1640	they	_
8-15	1641-1644	are	_
8-16	1645-1655	relatively	_
8-17	1656-1671	transdiagnostic	_
8-18	1672-1674	in	_
8-19	1675-1681	nature	_
8-20	1682-1683	.	_

9-1	1684-1689	These	_
9-2	1690-1698	findings	_
9-3	1699-1707	indicate	_
9-4	1708-1712	that	_
9-5	1713-1718	early	_
9-6	1719-1725	visual	_
9-7	1726-1736	processing	_
9-8	1737-1750	abnormalities	_
9-9	1751-1754	may	_
9-10	1755-1757	be	_
9-11	1758-1762	more	_
9-12	1763-1771	directly	_
9-13	1772-1779	related	_
9-14	1780-1782	to	_
9-15	1783-1791	specific	_
9-16	1792-1807	transdiagnostic	_
9-17	1808-1816	symptoms	_
9-18	1817-1821	such	_
9-19	1822-1824	as	_
9-20	1825-1834	delusions	_
9-21	1835-1838	and	_
9-22	1839-1850	constricted	_
9-23	1851-1857	affect	_
9-24	1858-1864	rather	_
9-25	1865-1869	than	_
9-26	1870-1878	specific	_
9-27	1879-1890	psychiatric	_
9-28	1891-1900	diagnoses	_
9-29	1901-1903	or	_
9-30	1904-1909	broad	_
9-31	1910-1917	symptom	_
9-32	1918-1924	factor	_
9-33	1925-1931	scales	_
9-34	1932-1933	.	_

10-1	1934-1935	4	_
10-2	1936-1937	.	_

11-1	1938-1945	Methods	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
11-2	1946-1949	4.1	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod
11-3	1950-1951	.	http://maven.renci.org/NeuroBridge/neurobridge#DataCollectionMethod

12-1	1952-1964	Participants	_
12-2	1965-1969	This	_
12-3	1970-1975	study	_
12-4	1976-1979	was	_
12-5	1980-1988	approved	_
12-6	1989-1991	by	_
12-7	1992-1995	the	_
12-8	1996-2009	Institutional	_
12-9	2010-2016	Review	_
12-10	2017-2022	Board	_
12-11	2023-2025	of	_
12-12	2026-2029	the	_
12-13	2030-2040	University	_
12-14	2041-2043	of	_
12-15	2044-2051	Central	_
12-16	2052-2059	Florida	_
12-17	2060-2063	and	_
12-18	2064-2071	follows	_
12-19	2072-2075	the	_
12-20	2076-2083	ethical	_
12-21	2084-2094	guidelines	_
12-22	2095-2104	described	_
12-23	2105-2107	in	_
12-24	2108-2111	the	_
12-25	2112-2123	Declaration	_
12-26	2124-2126	of	_
12-27	2127-2135	Helsinki	_
12-28	2136-2137	.	_

13-1	2138-2140	We	_
13-2	2141-2150	recruited	_
13-3	2151-2163	participants	_
13-4	2164-2169	using	_
13-5	2170-2173	two	_
13-6	2174-2183	different	_
13-7	2184-2189	types	_
13-8	2190-2192	of	_
13-9	2193-2207	advertisements	_
13-10	2208-2209	.	_

14-1	2210-2213	One	_
14-2	2214-2223	mentioned	_
14-3	2224-2228	that	_
14-4	2229-2231	we	_
14-5	2232-2236	were	_
14-6	2237-2244	looking	_
14-7	2245-2248	for	_
14-8	2249-2260	individuals	_
14-9	2261-2265	with	_
14-10	2266-2267	a	_
14-11	2268-2277	diagnosis	_
14-12	2278-2280	of	_
14-13	2281-2294	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-14	2295-2296	,	_
14-15	2297-2312	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
14-16	2313-2321	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
14-17	2322-2323	,	_
14-18	2324-2326	or	_
14-19	2327-2334	bipolar	_
14-20	2335-2343	disorder	_
14-21	2344-2345	,	_
14-22	2346-2351	while	_
14-23	2352-2355	the	_
14-24	2356-2361	other	_
14-25	2362-2371	mentioned	_
14-26	2372-2376	that	_
14-27	2377-2379	we	_
14-28	2380-2384	were	_
14-29	2385-2392	looking	_
14-30	2393-2396	for	_
14-31	2397-2403	adults	_
14-32	2404-2411	between	_
14-33	2412-2415	the	_
14-34	2416-2420	ages	_
14-35	2421-2423	of	_
14-36	2424-2426	21	_
14-37	2427-2430	and	_
14-38	2431-2433	55	_
14-39	2434-2435	.	_

15-1	2436-2441	These	_
15-2	2442-2456	advertisements	_
15-3	2457-2461	were	_
15-4	2462-2468	placed	_
15-5	2469-2471	in	_
15-6	2472-2473	a	_
15-7	2474-2481	variety	_
15-8	2482-2484	of	_
15-9	2485-2494	locations	_
15-10	2495-2504	including	_
15-11	2505-2510	local	_
15-12	2511-2522	psychiatric	_
15-13	2523-2533	facilities	_
15-14	2534-2535	,	_
15-15	2536-2541	local	_
15-16	2542-2552	newspapers	_
15-17	2553-2554	,	_
15-18	2555-2558	and	_
15-19	2559-2562	the	_
15-20	2563-2573	Craigslist	_
15-21	2574-2581	website	_
15-22	2582-2583	.	_

16-1	2584-2587	For	_
16-2	2588-2591	the	_
16-3	2592-2603	psychiatric	_
16-4	2604-2609	group	_
16-5	2610-2611	,	_
16-6	2612-2621	inclusion	_
16-7	2622-2630	criteria	_
16-8	2631-2639	included	_
16-9	2640-2646	having	_
16-10	2647-2650	any	_
16-11	2651-2662	psychiatric	_
16-12	2663-2672	diagnosis	_
16-13	2673-2674	,	_
16-14	2675-2679	even	_
16-15	2680-2686	though	_
16-16	2687-2701	advertisements	_
16-17	2702-2706	were	_
16-18	2707-2716	targeting	_
16-19	2717-2727	particular	_
16-20	2728-2732	ones	_
16-21	2733-2734	.	_

17-1	2735-2738	For	_
17-2	2739-2742	the	_
17-3	2743-2757	nonpsychiatric	_
17-4	2758-2763	group	_
17-5	2764-2765	,	_
17-6	2766-2769	the	_
17-7	2770-2778	presence	_
17-8	2779-2781	of	_
17-9	2782-2785	any	_
17-10	2786-2793	current	_
17-11	2794-2805	psychiatric	_
17-12	2806-2814	disorder	_
17-13	2815-2818	was	_
17-14	2819-2821	an	_
17-15	2822-2831	exclusion	_
17-16	2832-2840	criteria	_
17-17	2841-2842	,	_
17-18	2843-2845	as	_
17-19	2846-2849	was	_
17-20	2850-2856	having	_
17-21	2857-2858	a	_
17-22	2859-2869	biological	_
17-23	2870-2878	relative	_
17-24	2879-2883	with	_
17-25	2884-2885	a	_
17-26	2886-2895	psychotic	_
17-27	2896-2904	disorder	_
17-28	2905-2907	or	_
17-29	2908-2915	bipolar	_
17-30	2916-2924	disorder	_
17-31	2925-2926	.	_

18-1	2927-2930	For	_
18-2	2931-2935	both	_
18-3	2936-2942	groups	_
18-4	2943-2944	,	_
18-5	2945-2954	inclusion	_
18-6	2955-2963	criteria	_
18-7	2964-2972	included	_
18-8	2973-2978	being	_
18-9	2979-2986	between	_
18-10	2987-2990	the	_
18-11	2991-2995	ages	_
18-12	2996-2998	of	_
18-13	2999-3001	21	_
18-14	3002-3005	and	_
18-15	3006-3008	55	_
18-16	3009-3010	,	_
18-17	3011-3014	and	_
18-18	3015-3022	further	_
18-19	3023-3032	exclusion	_
18-20	3033-3041	criteria	_
18-21	3042-3050	included	_
18-22	3051-3052	:	_
18-23	3053-3060	history	_
18-24	3061-3063	of	_
18-25	3064-3065	a	_
18-26	3066-3078	neurological	_
18-27	3079-3087	disorder	_
18-28	3088-3089	,	_
18-29	3090-3098	seizures	_
18-30	3099-3100	,	_
18-31	3101-3103	or	_
18-32	3104-3108	head	_
18-33	3109-3115	injury	_
18-34	3116-3125	resulting	_
18-35	3126-3128	in	_
18-36	3129-3133	loss	_
18-37	3134-3136	of	_
18-38	3137-3150	consciousness	_
18-39	3151-3154	for	_
18-40	3155-3159	more	_
18-41	3160-3164	than	_
18-42	3165-3167	15	_
18-43	3168-3175	minutes	_
18-44	3176-3177	,	_
18-45	3178-3187	substance	_
18-46	3188-3193	abuse	_
18-47	3194-3196	or	_
18-48	3197-3207	dependence	_
18-49	3208-3210	in	_
18-50	3211-3214	the	_
18-51	3215-3219	last	_
18-52	3220-3223	six	_
18-53	3224-3230	months	_
18-54	3231-3232	(	_
18-55	3233-3236	per	_
18-56	3237-3247	diagnostic	_
18-57	3248-3257	interview	_
18-58	3258-3259	)	_
18-59	3260-3261	,	_
18-60	3262-3267	heavy	_
18-61	3268-3275	alcohol	_
18-62	3276-3279	use	_
18-63	3280-3282	or	_
18-64	3283-3286	any	_
18-65	3287-3291	drug	_
18-66	3292-3295	use	_
18-67	3296-3298	in	_
18-68	3299-3302	the	_
18-69	3303-3305	72	_
18-70	3306-3311	hours	_
18-71	3312-3317	prior	_
18-72	3318-3320	to	_
18-73	3321-3325	each	_
18-74	3326-3333	session	_
18-75	3334-3335	(	_
18-76	3336-3339	per	_
18-77	3340-3351	self-report	_
18-78	3352-3353	)	_
18-79	3354-3355	,	_
18-80	3356-3365	estimated	_
18-81	3366-3370	full	_
18-82	3371-3376	scale	_
18-83	3377-3379	IQ	_
18-84	3380-3381	<	_
18-85	3382-3384	70	_
18-86	3385-3386	,	_
18-87	3387-3393	visual	_
18-88	3394-3400	acuity	_
18-89	3401-3406	worse	_
18-90	3407-3411	than	_
18-91	3412-3417	20/50	_
18-92	3418-3419	(	_
18-93	3420-3428	allowing	_
18-94	3429-3432	for	_
18-95	3433-3443	corrective	_
18-96	3444-3450	lenses	_
18-97	3451-3452	)	_
18-98	3453-3454	,	_
18-99	3455-3458	and	_
18-100	3459-3469	indication	_
18-101	3470-3472	of	_
18-102	3473-3478	color	_
18-103	3479-3488	blindness	_
18-104	3489-3490	.	_

19-1	3491-3500	Following	_
19-2	3501-3502	a	_
19-3	3503-3508	phone	_
19-4	3509-3518	screening	_
19-5	3519-3520	,	_
19-6	3521-3529	eligible	_
19-7	3530-3542	participants	_
19-8	3543-3547	were	_
19-9	3548-3555	invited	_
19-10	3556-3558	to	_
19-11	3559-3562	the	_
19-12	3563-3568	first	_
19-13	3569-3571	of	_
19-14	3572-3575	two	_
19-15	3576-3584	sessions	_
19-16	3585-3586	.	_

20-1	3587-3599	Participants	_
20-2	3600-3604	were	_
20-3	3605-3613	provided	_
20-4	3614-3615	a	_
20-5	3616-3624	monetary	_
20-6	3625-3632	stipend	_
20-7	3633-3635	at	_
20-8	3636-3639	the	_
20-9	3640-3643	end	_
20-10	3644-3646	of	_
20-11	3647-3651	each	_
20-12	3652-3659	session	_
20-13	3660-3661	.	_

21-1	3662-3671	Following	_
21-2	3672-3683	recruitment	_
21-3	3684-3692	attempts	_
21-4	3693-3694	,	_
21-5	3695-3697	we	_
21-6	3698-3706	assessed	_
21-7	3707-3710	178	_
21-8	3711-3723	participants	_
21-9	3724-3726	in	_
21-10	3727-3730	the	_
21-11	3731-3736	first	_
21-12	3737-3739	of	_
21-13	3740-3743	the	_
21-14	3744-3747	two	_
21-15	3748-3756	sessions	_
21-16	3757-3758	.	_

22-1	3759-3761	Of	_
22-2	3762-3767	these	_
22-3	3768-3769	,	_
22-4	3770-3772	43	_
22-5	3773-3784	individuals	_
22-6	3785-3789	were	_
22-7	3790-3793	not	_
22-8	3794-3802	eligible	_
22-9	3803-3806	for	_
22-10	3807-3810	use	_
22-11	3811-3813	in	_
22-12	3814-3817	the	_
22-13	3818-3823	final	_
22-14	3824-3832	analyses	_
22-15	3833-3836	for	_
22-16	3837-3840	the	_
22-17	3841-3850	following	_
22-18	3851-3858	reasons	_
22-19	3859-3860	:	_
22-20	3861-3863	22	_
22-21	3864-3867	not	_
22-22	3868-3872	able	_
22-23	3873-3875	or	_
22-24	3876-3883	willing	_
22-25	3884-3886	to	_
22-26	3887-3893	return	_
22-27	3894-3896	to	_
22-28	3897-3900	the	_
22-29	3901-3907	second	_
22-30	3908-3915	session	_
22-31	3916-3917	,	_
22-32	3918-3919	5	_
22-33	3920-3923	had	_
22-34	3924-3933	substance	_
22-35	3934-3944	dependence	_
22-36	3945-3947	or	_
22-37	3948-3953	abuse	_
22-38	3954-3960	during	_
22-39	3961-3965	past	_
22-40	3966-3969	six	_
22-41	3970-3976	months	_
22-42	3977-3978	,	_
22-43	3979-3980	6	_
22-44	3981-3984	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
22-45	3985-3993	problems	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
22-46	3994-3995	,	_
22-47	3996-3997	3	_
22-48	3998-4006	problems	_
22-49	4007-4018	calibrating	_
22-50	4019-4022	the	_
22-51	4023-4026	eye	_
22-52	4027-4034	tracker	_
22-53	4035-4036	,	_
22-54	4037-4038	3	_
22-55	4039-4045	visual	_
22-56	4046-4052	acuity	_
22-57	4053-4058	worse	_
22-58	4059-4063	than	_
22-59	4064-4069	20/50	_
22-60	4070-4071	,	_
22-61	4072-4073	2	_
22-62	4074-4083	excessive	_
22-63	4084-4094	drowsiness	_
22-64	4095-4101	during	_
22-65	4102-4105	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
22-66	4106-4115	recording	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
22-67	4116-4117	,	_
22-68	4118-4119	1	_
22-69	4120-4125	color	_
22-70	4126-4135	blindness	_
22-71	4136-4137	,	_
22-72	4138-4141	and	_
22-73	4142-4143	1	_
22-74	4144-4153	estimated	_
22-75	4154-4156	IQ	_
22-76	4157-4158	<	_
22-77	4159-4161	70	_
22-78	4162-4163	.	_

23-1	4164-4168	This	_
23-2	4169-4177	resulted	_
23-3	4178-4180	in	_
23-4	4181-4184	135	_
23-5	4185-4197	participants	_
23-6	4198-4206	included	_
23-7	4207-4209	in	_
23-8	4210-4213	the	_
23-9	4214-4219	final	_
23-10	4220-4228	analyses	_
23-11	4229-4230	.	_

24-1	4231-4236	While	_
24-2	4237-4243	sample	_
24-3	4244-4253	diagnoses	_
24-4	4254-4257	are	_
24-5	4258-4265	similar	_
24-6	4266-4268	to	_
24-7	4269-4272	our	_
24-8	4273-4283	previously	_
24-9	4284-4293	published	_
24-10	4294-4299	study	_
24-11	4300-4302	on	_
24-12	4303-4316	visual-evoked	_
24-13	4317-4327	potentials	_
24-14	4328-4329	,	_
24-15	4330-4334	only	_
24-16	4335-4339	five	_
24-17	4340-4342	of	_
24-18	4343-4348	those	_
24-19	4349-4360	individuals	_
24-20	4361-4373	participated	_
24-21	4374-4376	in	_
24-22	4377-4380	the	_
24-23	4381-4388	current	_
24-24	4389-4394	study	_
24-25	4395-4396	.	_

25-1	4397-4400	See	_
25-2	4401-4406	Table	_
25-3	4407-4408	1	_
25-4	4409-4412	for	_
25-5	4413-4424	demographic	_
25-6	4425-4428	and	_
25-7	4429-4437	clinical	_
25-8	4438-4453	characteristics	_
25-9	4454-4455	.	_

26-1	4456-4465	Diagnoses	_
26-2	4466-4468	by	_
26-3	4469-4474	broad	_
26-4	4475-4482	classes	_
26-5	4483-4491	included	_
26-6	4492-4493	:	_
26-7	4494-4495	1	_
26-8	4496-4497	)	_
26-9	4498-4500	no	_
26-10	4501-4508	current	_
26-11	4509-4520	psychiatric	_
26-12	4521-4529	disorder	_
26-13	4530-4531	(	_
26-14	4532-4533	N	_
26-15	4534-4535	=	_
26-16	4536-4538	62	_
26-17	4539-4540	[	_
26-18	4541-4543	46	_
26-19	4544-4545	%	_
26-20	4546-4547	]	_
26-21	4548-4549	)	_
26-22	4550-4551	;	_
26-23	4552-4553	2	_
26-24	4554-4555	)	_
26-25	4556-4563	bipolar	_
26-26	4564-4573	disorders	_
26-27	4574-4575	(	_
26-28	4576-4577	N	_
26-29	4578-4579	=	_
26-30	4580-4582	26	_
26-31	4583-4584	[	_
26-32	4585-4587	19	_
26-33	4588-4589	%	_
26-34	4590-4591	]	_
26-35	4592-4593	;	_
26-36	4594-4596	24	_
26-37	4597-4604	bipolar	_
26-38	4605-4606	I	_
26-39	4607-4615	disorder	_
26-40	4616-4617	[	_
26-41	4618-4619	7	_
26-42	4620-4624	with	_
26-43	4625-4634	psychotic	_
26-44	4635-4643	features	_
26-45	4644-4645	]	_
26-46	4646-4649	and	_
26-47	4650-4651	2	_
26-48	4652-4659	bipolar	_
26-49	4660-4668	disorder	_
26-50	4669-4672	not	_
26-51	4673-4682	otherwise	_
26-52	4683-4692	specified	_
26-53	4693-4694	)	_
26-54	4695-4696	;	_
26-55	4697-4698	3	_
26-56	4699-4700	)	_
26-57	4701-4714	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
26-58	4715-4723	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
26-59	4724-4732	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
26-60	4733-4734	(	_
26-61	4735-4736	N	_
26-62	4737-4738	=	_
26-63	4739-4741	25	_
26-64	4742-4743	[	_
26-65	4744-4746	19	_
26-66	4747-4748	%	_
26-67	4749-4750	]	_
26-68	4751-4752	;	_
26-69	4753-4755	15	_
26-70	4756-4769	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
26-71	4770-4771	,	_
26-72	4772-4773	4	_
26-73	4774-4789	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
26-74	4790-4798	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
26-75	4799-4800	,	_
26-76	4801-4802	2	_
26-77	4803-4813	delusional	_
26-78	4814-4822	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MovementDisorder
26-79	4823-4824	,	_
26-80	4825-4828	and	_
26-81	4829-4830	3	_
26-82	4831-4842	schizotypal	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire
26-83	4843-4846	and	_
26-84	4847-4848	1	_
26-85	4849-4857	paranoid	_
26-86	4858-4869	personality	_
26-87	4870-4878	disorder	_
26-88	4879-4880	)	_
26-89	4881-4882	;	_
26-90	4883-4886	and	_
26-91	4887-4888	4	_
26-92	4889-4890	)	_
26-93	4891-4900	recurrent	_
26-94	4901-4903	or	_
26-95	4904-4911	current	_
26-96	4912-4920	unipolar	_
26-97	4921-4931	depressive	_
26-98	4932-4941	disorders	_
26-99	4942-4943	(	_
26-100	4944-4945	N	_
26-101	4946-4947	=	_
26-102	4948-4950	19	_
26-103	4951-4952	[	_
26-104	4953-4955	14	_
26-105	4956-4957	%	_
26-106	4958-4959	]	_
26-107	4960-4961	;	_
26-108	4962-4964	14	_
26-109	4965-4970	major	_
26-110	4971-4981	depressive	_
26-111	4982-4990	disorder	_
26-112	4991-4992	,	_
26-113	4993-5002	recurrent	_
26-114	5003-5004	[	_
26-115	5005-5006	2	_
26-116	5007-5011	with	_
26-117	5012-5021	psychotic	_
26-118	5022-5030	features	_
26-119	5031-5032	]	_
26-120	5033-5034	,	_
26-121	5035-5036	2	_
26-122	5037-5042	major	_
26-123	5043-5053	depressive	_
26-124	5054-5062	disorder	_
26-125	5063-5064	,	_
26-126	5065-5071	single	_
26-127	5072-5079	episode	_
26-128	5080-5081	[	_
26-129	5082-5089	current	_
26-130	5090-5091	]	_
26-131	5092-5093	,	_
26-132	5094-5095	2	_
26-133	5096-5105	dysthymic	_
26-134	5106-5114	disorder	_
26-135	5115-5116	,	_
26-136	5117-5120	and	_
26-137	5121-5122	1	_
26-138	5123-5133	depressive	_
26-139	5134-5142	disorder	_
26-140	5143-5146	not	_
26-141	5147-5156	otherwise	_
26-142	5157-5166	specified	_
26-143	5167-5168	)	_
26-144	5169-5170	.	_

27-1	5171-5186	Transdiagnostic	_
27-2	5187-5195	analyses	_
27-3	5196-5200	also	_
27-4	5201-5209	included	_
27-5	5210-5215	three	_
27-6	5216-5228	participants	_
27-7	5229-5233	with	_
27-8	5234-5239	other	_
27-9	5240-5247	current	_
27-10	5248-5259	psychiatric	_
27-11	5260-5269	disorders	_
27-12	5270-5271	:	_
27-13	5272-5273	1	_
27-14	5274-5284	adjustment	_
27-15	5285-5293	disorder	_
27-16	5294-5298	with	_
27-17	5299-5306	anxiety	_
27-18	5307-5308	,	_
27-19	5309-5310	1	_
27-20	5311-5317	social	_
27-21	5318-5324	phobia	_
27-22	5325-5326	,	_
27-23	5327-5330	and	_
27-24	5331-5332	1	_
27-25	5333-5342	obsessive	_
27-26	5343-5353	compulsive	_
27-27	5354-5362	disorder	_
27-28	5363-5364	.	_

28-1	5365-5368	The	_
28-2	5369-5373	four	_
28-3	5374-5384	diagnostic	_
28-4	5385-5390	class	_
28-5	5391-5397	groups	_
28-6	5398-5401	did	_
28-7	5402-5405	not	_
28-8	5406-5412	differ	_
28-9	5413-5415	on	_
28-10	5416-5419	age	_
28-11	5420-5421	,	_
28-12	5422-5423	F	_
28-13	5424-5425	(	_
28-14	5426-5431	3,131	_
28-15	5432-5433	)	_
28-16	5434-5435	=	_
28-17	5436-5440	0.26	_
28-18	5441-5442	,	_
28-19	5443-5444	p	_
28-20	5445-5446	=	_
28-21	5447-5450	.85	_
28-22	5451-5452	,	_
28-23	5453-5455	η2	_
28-24	5456-5457	=	_
28-25	5458-5462	.006	_
28-26	5463-5464	,	_
28-27	5465-5468	sex	_
28-28	5469-5470	,	_
28-29	5471-5473	χ2	_
28-30	5474-5475	(	_
28-31	5476-5477	3	_
28-32	5478-5479	,	_
28-33	5480-5481	N	_
28-34	5482-5483	=	_
28-35	5484-5487	135	_
28-36	5488-5489	)	_
28-37	5490-5491	=	_
28-38	5492-5496	2.21	_
28-39	5497-5498	,	_
28-40	5499-5500	p	_
28-41	5501-5502	=	_
28-42	5503-5506	.53	_
28-43	5507-5508	,	_
28-44	5509-5513	race	_
28-45	5514-5515	,	_
28-46	5516-5518	χ2	_
28-47	5519-5520	(	_
28-48	5521-5522	9	_
28-49	5523-5524	,	_
28-50	5525-5526	N	_
28-51	5527-5528	=	_
28-52	5529-5532	135	_
28-53	5533-5534	)	_
28-54	5535-5536	=	_
28-55	5537-5542	13.54	_
28-56	5543-5544	,	_
28-57	5545-5546	p	_
28-58	5547-5548	=	_
28-59	5549-5552	.14	_
28-60	5553-5554	,	_
28-61	5555-5557	or	_
28-62	5558-5573	Hispanic/Latino	_
28-63	5574-5575	(	_
28-64	5576-5577	a	_
28-65	5578-5579	)	_
28-66	5580-5589	ethnicity	_
28-67	5590-5592	χ2	_
28-68	5593-5594	(	_
28-69	5595-5596	3	_
28-70	5597-5598	,	_
28-71	5599-5600	N	_
28-72	5601-5602	=	_
28-73	5603-5606	135	_
28-74	5607-5608	)	_
28-75	5609-5610	=	_
28-76	5611-5615	1.75	_
28-77	5616-5617	,	_
28-78	5618-5619	p	_
28-79	5620-5621	=	_
28-80	5622-5625	.63	_
28-81	5626-5627	.	_

29-1	5628-5635	However	_
29-2	5636-5637	,	_
29-3	5638-5643	level	_
29-4	5644-5646	of	_
29-5	5647-5656	education	_
29-6	5657-5665	differed	_
29-7	5666-5673	between	_
29-8	5674-5677	the	_
29-9	5678-5682	four	_
29-10	5683-5689	groups	_
29-11	5690-5691	(	_
29-12	5692-5695	see	_
29-13	5696-5701	Table	_
29-14	5702-5703	1	_
29-15	5704-5705	)	_
29-16	5706-5707	,	_
29-17	5708-5709	F	_
29-18	5710-5711	(	_
29-19	5712-5717	3,131	_
29-20	5718-5719	)	_
29-21	5720-5721	=	_
29-22	5722-5726	6.95	_
29-23	5727-5728	,	_
29-24	5729-5730	p	_
29-25	5731-5732	<	_
29-26	5733-5737	.001	_
29-27	5738-5739	,	_
29-28	5740-5742	η2	_
29-29	5743-5744	=	_
29-30	5745-5748	.14	_
29-31	5749-5750	.	_

30-1	5751-5754	The	_
30-2	5755-5757	no	_
30-3	5758-5765	current	_
30-4	5766-5777	psychiatric	_
30-5	5778-5786	disorder	_
30-6	5787-5792	group	_
30-7	5793-5796	had	_
30-8	5797-5798	a	_
30-9	5799-5812	significantly	_
30-10	5813-5819	higher	_
30-11	5820-5825	level	_
30-12	5826-5828	of	_
30-13	5829-5838	education	_
30-14	5839-5841	as	_
30-15	5842-5850	compared	_
30-16	5851-5853	to	_
30-17	5854-5857	the	_
30-18	5858-5868	depressive	_
30-19	5869-5870	,	_
30-20	5871-5872	F	_
30-21	5873-5874	(	_
30-22	5875-5879	1,82	_
30-23	5880-5881	)	_
30-24	5882-5883	=	_
30-25	5884-5888	7.41	_
30-26	5889-5890	,	_
30-27	5891-5892	p	_
30-28	5893-5894	=	_
30-29	5895-5898	.01	_
30-30	5899-5900	,	_
30-31	5901-5903	η2	_
30-32	5904-5905	=	_
30-33	5906-5909	.08	_
30-34	5910-5911	,	_
30-35	5912-5915	and	_
30-36	5916-5929	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
30-37	5930-5938	spectrum	_
30-38	5939-5940	,	_
30-39	5941-5942	F	_
30-40	5943-5944	(	_
30-41	5945-5949	1,88	_
30-42	5950-5951	)	_
30-43	5952-5953	=	_
30-44	5954-5958	9.86	_
30-45	5959-5960	,	_
30-46	5961-5962	p	_
30-47	5963-5964	=	_
30-48	5965-5969	.002	_
30-49	5970-5971	,	_
30-50	5972-5974	η2	_
30-51	5975-5976	=	_
30-52	5977-5980	.10	_
30-53	5981-5982	,	_
30-54	5983-5991	disorder	_
30-55	5992-5998	groups	_
30-56	5999-6000	,	_
30-57	6001-6004	who	_
30-58	6005-6008	did	_
30-59	6009-6012	not	_
30-60	6013-6019	differ	_
30-61	6020-6024	from	_
30-62	6025-6029	each	_
30-63	6030-6035	other	_
30-64	6036-6037	,	_
30-65	6038-6039	F	_
30-66	6040-6041	(	_
30-67	6042-6046	1,42	_
30-68	6047-6048	)	_
30-69	6049-6050	=	_
30-70	6051-6055	0.01	_
30-71	6056-6057	,	_
30-72	6058-6059	p	_
30-73	6060-6061	=	_
30-74	6062-6065	.95	_
30-75	6066-6067	,	_
30-76	6068-6070	η2	_
30-77	6071-6072	<	_
30-78	6073-6077	.001	_
30-79	6078-6079	.	_

31-1	6080-6083	The	_
31-2	6084-6091	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
31-3	6092-6101	disorders	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
31-4	6102-6107	group	_
31-5	6108-6111	had	_
31-6	6112-6113	a	_
31-7	6114-6127	significantly	_
31-8	6128-6134	higher	_
31-9	6135-6140	level	_
31-10	6141-6143	of	_
31-11	6144-6153	education	_
31-12	6154-6158	than	_
31-13	6159-6162	the	_
31-14	6163-6173	depressive	http://maven.renci.org/NeuroBridge/neurobridge#DepressiveDisorder
31-15	6174-6175	,	_
31-16	6176-6177	F	_
31-17	6178-6179	(	_
31-18	6180-6184	1,43	_
31-19	6185-6186	)	_
31-20	6187-6188	=	_
31-21	6189-6193	9.34	_
31-22	6194-6195	,	_
31-23	6196-6197	p	_
31-24	6198-6199	=	_
31-25	6200-6204	.004	_
31-26	6205-6206	,	_
31-27	6207-6209	η2	_
31-28	6210-6211	=	_
31-29	6212-6215	.18	_
31-30	6216-6217	,	_
31-31	6218-6221	and	_
31-32	6222-6235	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
31-33	6236-6244	spectrum	_
31-34	6245-6246	,	_
31-35	6247-6248	F	_
31-36	6249-6250	(	_
31-37	6251-6255	1,49	_
31-38	6256-6257	)	_
31-39	6258-6259	=	_
31-40	6260-6265	12.11	_
31-41	6266-6267	,	_
31-42	6268-6269	p	_
31-43	6270-6271	=	_
31-44	6272-6276	.001	_
31-45	6277-6278	,	_
31-46	6279-6281	η2	_
31-47	6282-6283	=	_
31-48	6284-6287	.20	_
31-49	6288-6289	,	_
31-50	6290-6298	disorder	_
31-51	6299-6305	groups	_
31-52	6306-6307	,	_
31-53	6308-6311	but	_
31-54	6312-6315	did	_
31-55	6316-6319	not	_
31-56	6320-6326	differ	_
31-57	6327-6331	from	_
31-58	6332-6335	the	_
31-59	6336-6338	no	_
31-60	6339-6346	current	_
31-61	6347-6355	disorder	_
31-62	6356-6361	group	_
31-63	6362-6363	,	_
31-64	6364-6365	F	_
31-65	6366-6367	(	_
31-66	6368-6372	1,89	_
31-67	6373-6374	)	_
31-68	6375-6376	=	_
31-69	6377-6381	2.25	_
31-70	6382-6383	,	_
31-71	6384-6385	p	_
31-72	6386-6387	=	_
31-73	6388-6391	.14	_
31-74	6392-6393	,	_
31-75	6394-6396	η2	_
31-76	6397-6398	=	_
31-77	6399-6402	.03	_
31-78	6403-6404	.	_

32-1	6405-6408	4.2	_
32-2	6409-6410	.	_

33-1	6411-6421	Procedures	_
33-2	6422-6425	Due	_
33-3	6426-6428	to	_
33-4	6429-6432	the	_
33-5	6433-6439	length	_
33-6	6440-6442	of	_
33-7	6443-6446	the	_
33-8	6447-6457	procedures	_
33-9	6458-6459	,	_
33-10	6460-6463	the	_
33-11	6464-6469	study	_
33-12	6470-6473	was	_
33-13	6474-6486	administered	_
33-14	6487-6491	over	_
33-15	6492-6495	two	_
33-16	6496-6504	meetings	_
33-17	6505-6507	of	_
33-18	6508-6521	approximately	_
33-19	6522-6525	two	_
33-20	6526-6528	to	_
33-21	6529-6534	three	_
33-22	6535-6540	hours	_
33-23	6541-6542	,	_
33-24	6543-6548	which	_
33-25	6549-6553	were	_
33-26	6554-6559	19.76	_
33-27	6560-6564	days	_
33-28	6565-6570	apart	_
33-29	6571-6573	on	_
33-30	6574-6581	average	_
33-31	6582-6583	,	_
33-32	6584-6588	with	_
33-33	6589-6592	six	_
33-34	6593-6605	participants	_
33-35	6606-6616	completing	_
33-36	6617-6621	both	_
33-37	6622-6630	sessions	_
33-38	6631-6633	on	_
33-39	6634-6637	the	_
33-40	6638-6642	same	_
33-41	6643-6646	day	_
33-42	6647-6648	.	_

34-1	6649-6651	In	_
34-2	6652-6657	cases	_
34-3	6658-6660	in	_
34-4	6661-6666	which	_
34-5	6667-6671	more	_
34-6	6672-6676	than	_
34-7	6677-6678	a	_
34-8	6679-6684	month	_
34-9	6685-6692	elapsed	_
34-10	6693-6700	between	_
34-11	6701-6709	sessions	_
34-12	6710-6711	(	_
34-13	6712-6713	N	_
34-14	6714-6715	=	_
34-15	6716-6718	26	_
34-16	6719-6720	)	_
34-17	6721-6722	,	_
34-18	6723-6726	the	_
34-19	6727-6749	clinician-administered	_
34-20	6750-6760	diagnostic	_
34-21	6761-6771	interviews	_
34-22	6772-6775	and	_
34-23	6776-6783	symptom	_
34-24	6784-6792	measures	_
34-25	6793-6797	were	_
34-26	6798-6813	re-administered	_
34-27	6814-6816	to	_
34-28	6817-6824	reflect	_
34-29	6825-6828	any	_
34-30	6829-6836	changes	_
34-31	6837-6838	.	_

35-1	6839-6844	4.2.1	http://maven.renci.org/NeuroBridge/neurobridge#Thing
35-2	6845-6846	.	_

36-1	6847-6854	Session	_
36-2	6855-6856	#	_
36-3	6857-6858	1	_
36-4	6859-6869	Procedures	_
36-5	6870-6875	After	_
36-6	6876-6878	an	_
36-7	6879-6887	informed	_
36-8	6888-6895	consent	_
36-9	6896-6905	procedure	_
36-10	6906-6907	,	_
36-11	6908-6920	participants	_
36-12	6921-6930	completed	_
36-13	6931-6934	the	_
36-14	6935-6947	Colenbrander	http://maven.renci.org/NeuroBridge/neurobridge#enhancedMagneticResonanceImaging
36-15	6948-6953	Mixed	http://maven.renci.org/NeuroBridge/neurobridge#enhancedMagneticResonanceImaging
36-16	6954-6962	Contrast	http://maven.renci.org/NeuroBridge/neurobridge#enhancedMagneticResonanceImaging
36-17	6963-6967	Card	http://maven.renci.org/NeuroBridge/neurobridge#enhancedMagneticResonanceImaging
36-18	6968-6971	Set	http://maven.renci.org/NeuroBridge/neurobridge#enhancedMagneticResonanceImaging
36-19	6972-6973	(	_
36-20	6974-6983	Precision	_
36-21	6984-6990	Vision	_
36-22	6991-6992	,	_
36-23	6993-6995	La	_
36-24	6996-7001	Salle	_
36-25	7002-7003	,	_
36-26	7004-7006	IL	_
36-27	7007-7008	)	_
36-28	7009-7011	to	_
36-29	7012-7020	estimate	_
36-30	7021-7027	visual	_
36-31	7028-7034	acuity	_
36-32	7035-7036	.	_

37-1	7037-7049	Participants	_
37-2	7050-7054	with	_
37-3	7055-7056	a	_
37-4	7057-7066	corrected	_
37-5	7067-7073	visual	_
37-6	7074-7080	acuity	_
37-7	7081-7086	worse	_
37-8	7087-7091	than	_
37-9	7092-7097	20/50	_
37-10	7098-7100	at	_
37-11	7101-7103	an	_
37-12	7104-7116	intermediate	_
37-13	7117-7125	distance	_
37-14	7126-7130	were	_
37-15	7131-7139	excluded	_
37-16	7140-7141	,	_
37-17	7142-7144	as	_
37-18	7145-7149	were	_
37-19	7150-7162	participants	_
37-20	7163-7173	exhibiting	_
37-21	7174-7179	color	_
37-22	7180-7189	blindness	_
37-23	7190-7195	using	_
37-24	7196-7204	Ishihara	_
37-25	7205-7207	's	_
37-26	7208-7213	Tests	_
37-27	7214-7217	for	_
37-28	7218-7224	Colour	_
37-29	7225-7235	Deficiency	_
37-30	7236-7237	(	_
37-31	7238-7246	Kanehara	_
37-32	7247-7254	Trading	_
37-33	7255-7259	Inc.	_
37-34	7260-7261	,	_
37-35	7262-7267	Tokyo	_
37-36	7268-7269	,	_
37-37	7270-7275	Japan	_
37-38	7276-7277	)	_
37-39	7278-7279	.	_

38-1	7280-7292	Participants	_
38-2	7293-7302	completed	_
38-3	7303-7306	the	_
38-4	7307-7311	Wide	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
38-5	7312-7317	Range	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
38-6	7318-7329	Achievement	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
38-7	7330-7334	Test	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
38-8	7335-7336	–	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
38-9	7337-7340	4th	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
38-10	7341-7348	edition	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
38-11	7349-7350	(	_
38-12	7351-7357	WRAT-4	http://maven.renci.org/NeuroBridge/neurobridge#RatingScale
38-13	7358-7359	)	http://maven.renci.org/NeuroBridge/neurobridge#RatingScale
38-14	7360-7367	Reading	_
38-15	7368-7375	subtest	_
38-16	7376-7378	to	_
38-17	7379-7387	estimate	_
38-18	7388-7392	full	_
38-19	7393-7398	scale	_
38-20	7399-7401	IQ	_
38-21	7402-7403	,	_
38-22	7404-7407	and	_
38-23	7408-7412	were	_
38-24	7413-7421	excluded	_
38-25	7422-7424	if	_
38-26	7425-7428	the	_
38-27	7429-7441	standardized	_
38-28	7442-7447	score	_
38-29	7448-7451	was	_
38-30	7452-7456	less	_
38-31	7457-7461	than	_
38-32	7462-7464	70	_
38-33	7465-7466	.	_

39-1	7467-7468	A	_
39-2	7469-7476	trained	_
39-3	7477-7485	clinical	_
39-4	7486-7496	psychology	_
39-5	7497-7505	doctoral	_
39-6	7506-7513	student	_
39-7	7514-7526	administered	_
39-8	7527-7530	the	_
39-9	7531-7541	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-10	7542-7550	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-11	7551-7560	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-12	7561-7564	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-13	7565-7571	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-14	7572-7576	Axis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-15	7577-7578	I	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-16	7579-7588	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-17	7589-7590	,	_
39-18	7591-7594	the	_
39-19	7595-7606	schizotypal	_
39-20	7607-7608	,	_
39-21	7609-7617	paranoid	_
39-22	7618-7619	,	_
39-23	7620-7623	and	_
39-24	7624-7632	avoidant	_
39-25	7633-7644	personality	_
39-26	7645-7653	disorder	_
39-27	7654-7655	(	_
39-28	7656-7660	i.e.	_
39-29	7661-7662	,	_
39-30	7663-7685	schizophrenia-spectrum	_
39-31	7686-7687	)	_
39-32	7688-7696	sections	_
39-33	7697-7699	of	_
39-34	7700-7703	the	_
39-35	7704-7714	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-36	7715-7723	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-37	7724-7733	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-38	7734-7737	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-39	7738-7744	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-40	7745-7749	Axis	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-41	7750-7752	II	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-42	7753-7762	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
39-43	7763-7764	,	_
39-44	7765-7768	and	_
39-45	7769-7772	the	_
39-46	7773-7783	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
39-47	7784-7793	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
39-48	7794-7797	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
39-49	7798-7806	Positive	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
39-50	7807-7810	and	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
39-51	7811-7819	Negative	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
39-52	7820-7829	Syndromes	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
39-53	7830-7832	of	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
39-54	7833-7846	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
39-55	7847-7848	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
39-56	7849-7854	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
39-57	7855-7856	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredInterviewforProdromalSyndromesRatingScale
39-58	7857-7858	.	_

40-1	7859-7864	Final	_
40-2	7865-7874	diagnoses	_
40-3	7875-7879	were	_
40-4	7880-7890	determined	_
40-5	7891-7898	through	_
40-6	7899-7903	case	_
40-7	7904-7917	presentations	_
40-8	7918-7922	with	_
40-9	7923-7924	a	_
40-10	7925-7933	licensed	_
40-11	7934-7946	psychologist	_
40-12	7947-7948	(	_
40-13	7949-7955	author	_
40-14	7956-7959	JSB	_
40-15	7960-7961	)	_
40-16	7962-7963	.	_

41-1	7964-7976	Participants	_
41-2	7977-7981	also	_
41-3	7982-7991	completed	_
41-4	7992-7995	the	_
41-5	7996-8007	Schizotypal	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire
41-6	8008-8019	Personality	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire
41-7	8020-8033	Questionnaire	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire
41-8	8034-8035	–	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire
41-9	8036-8041	Brief	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire
41-10	8042-8049	Revised	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire
41-11	8050-8051	(	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire
41-12	8052-8058	SPQ-BR	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire
41-13	8059-8060	)	http://maven.renci.org/NeuroBridge/neurobridge#SchizotypalPersonalityQuestionnaire
41-14	8061-8062	,	_
41-15	8063-8066	and	_
41-16	8067-8070	the	_
41-17	8071-8083	Anticipatory	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
41-18	8084-8087	and	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
41-19	8088-8100	Consummatory	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
41-20	8101-8114	Interpersonal	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
41-21	8115-8123	Pleasure	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
41-22	8124-8129	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
41-23	8130-8131	(	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
41-24	8132-8137	ACIPS	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
41-25	8138-8139	)	http://maven.renci.org/NeuroBridge/neurobridge#PersonalandSocialPerformanceScale
41-26	8140-8141	.	_

42-1	8142-8154	Participants	_
42-2	8155-8159	were	_
42-3	8160-8167	invited	_
42-4	8168-8170	to	_
42-5	8171-8178	Session	_
42-6	8179-8180	#	_
42-7	8181-8182	2	_
42-8	8183-8185	if	_
42-9	8186-8190	they	_
42-10	8191-8197	passed	_
42-11	8198-8201	the	_
42-12	8202-8211	exclusion	_
42-13	8212-8220	criteria	_
42-14	8221-8227	listed	_
42-15	8228-8233	above	_
42-16	8234-8235	,	_
42-17	8236-8239	and	_
42-18	8240-8243	did	_
42-19	8244-8247	not	_
42-20	8248-8252	meet	_
42-21	8253-8263	diagnostic	_
42-22	8264-8272	criteria	_
42-23	8273-8276	for	_
42-24	8277-8278	a	_
42-25	8279-8288	substance	_
42-26	8289-8292	use	_
42-27	8293-8301	disorder	_
42-28	8302-8304	in	_
42-29	8305-8308	the	_
42-30	8309-8313	past	_
42-31	8314-8317	six	_
42-32	8318-8324	months	_
42-33	8325-8326	.	_

43-1	8327-8332	4.2.2	_
43-2	8333-8334	.	_

44-1	8335-8342	Session	_
44-2	8343-8344	#	_
44-3	8345-8346	2	_
44-4	8347-8357	Procedures	_
44-5	8358-8363	After	_
44-6	8364-8366	an	_
44-7	8367-8375	informed	_
44-8	8376-8383	consent	_
44-9	8384-8393	procedure	_
44-10	8394-8395	,	_
44-11	8396-8408	participants	_
44-12	8409-8418	completed	_
44-13	8419-8422	the	_
44-14	8423-8429	visual	_
44-15	8430-8436	evoked	_
44-16	8437-8446	potential	_
44-17	8447-8451	task	_
44-18	8452-8453	.	_

45-1	8454-8461	Stimuli	_
45-2	8462-8471	consisted	_
45-3	8472-8474	of	_
45-4	8475-8476	8	_
45-5	8477-8478	×	_
45-6	8479-8480	8	_
45-7	8481-8487	arrays	_
45-8	8488-8490	of	_
45-9	8491-8497	checks	_
45-10	8498-8499	,	_
45-11	8500-8502	as	_
45-12	8503-8507	used	_
45-13	8508-8510	in	_
45-14	8511-8518	several	_
45-15	8519-8524	other	_
45-16	8525-8534	transient	_
45-17	8535-8538	VEP	_
45-18	8539-8551	publications	_
45-19	8552-8553	.	_

46-1	8554-8561	E-Prime	_
46-2	8562-8565	2.0	_
46-3	8566-8578	Professional	_
46-4	8579-8582	was	_
46-5	8583-8587	used	_
46-6	8588-8591	for	_
46-7	8592-8599	stimuli	_
46-8	8600-8612	presentation	_
46-9	8613-8614	.	_

47-1	8615-8618	The	_
47-2	8619-8624	array	_
47-3	8625-8627	of	_
47-4	8628-8632	gray	_
47-5	8633-8639	checks	_
47-6	8640-8648	appeared	_
47-7	8649-8651	in	_
47-8	8652-8655	the	_
47-9	8656-8662	center	_
47-10	8663-8665	of	_
47-11	8666-8669	the	_
47-12	8670-8677	monitor	_
47-13	8678-8684	screen	_
47-14	8685-8686	(	_
47-15	8687-8690	see	_
47-16	8691-8697	Figure	_
47-17	8698-8699	5	_
47-18	8700-8701	)	_
47-19	8702-8703	,	_
47-20	8704-8714	subtending	_
47-21	8715-8716	a	_
47-22	8717-8723	visual	_
47-23	8724-8729	angle	_
47-24	8730-8732	of	_
47-25	8733-8737	6.67	_
47-26	8738-8739	×	_
47-27	8740-8744	6.67	_
47-28	8745-8752	degrees	_
47-29	8753-8754	.	_

48-1	8755-8758	The	_
48-2	8759-8765	checks	_
48-3	8766-8770	were	_
48-4	8771-8780	presented	_
48-5	8781-8783	on	_
48-6	8784-8789	three	_
48-7	8790-8799	different	_
48-8	8800-8811	backgrounds	_
48-9	8812-8814	of	_
48-10	8815-8819	gray	_
48-11	8820-8821	,	_
48-12	8822-8827	green	_
48-13	8828-8829	,	_
48-14	8830-8833	and	_
48-15	8834-8837	red	_
48-16	8838-8839	,	_
48-17	8840-8845	which	_
48-18	8846-8856	surrounded	_
48-19	8857-8860	the	_
48-20	8861-8867	checks	_
48-21	8868-8871	and	_
48-22	8872-8875	the	_
48-23	8876-8880	rest	_
48-24	8881-8883	of	_
48-25	8884-8887	the	_
48-26	8888-8894	screen	_
48-27	8895-8896	,	_
48-28	8897-8907	subtending	_
48-29	8908-8909	a	_
48-30	8910-8916	visual	_
48-31	8917-8922	angle	_
48-32	8923-8925	of	_
48-33	8926-8931	32.48	_
48-34	8932-8933	×	_
48-35	8934-8939	18.53	_
48-36	8940-8947	degrees	_
48-37	8948-8949	.	_

49-1	8950-8953	The	_
49-2	8954-8958	gray	_
49-3	8959-8969	background	_
49-4	8970-8973	was	_
49-5	8974-8980	chosen	_
49-6	8981-8983	as	_
49-7	8984-8987	the	_
49-8	8988-8995	primary	_
49-9	8996-9004	baseline	_
49-10	9005-9010	color	_
49-11	9011-9013	to	_
49-12	9014-9019	allow	_
49-13	9020-9023	for	_
49-14	9024-9034	comparison	_
49-15	9035-9037	to	_
49-16	9038-9041	VEP	_
49-17	9042-9049	studies	_
49-18	9050-9054	from	_
49-19	9055-9060	other	_
49-20	9061-9065	labs	_
49-21	9066-9067	.	_

50-1	9068-9070	We	_
50-2	9071-9075	also	_
50-3	9076-9079	had	_
50-4	9080-9088	specific	_
50-5	9089-9097	interest	_
50-6	9098-9100	in	_
50-7	9101-9104	the	_
50-8	9105-9111	effect	_
50-9	9112-9114	of	_
50-10	9115-9118	the	_
50-11	9119-9122	red	_
50-12	9123-9133	background	_
50-13	9134-9135	,	_
50-14	9136-9138	so	_
50-15	9139-9144	green	_
50-16	9145-9148	was	_
50-17	9149-9157	included	_
50-18	9158-9161	for	_
50-19	9162-9166	that	_
50-20	9167-9177	comparison	_
50-21	9178-9180	as	_
50-22	9181-9183	it	_
50-23	9184-9186	is	_
50-24	9187-9190	the	_
50-25	9191-9199	opponent	_
50-26	9200-9205	color	_
50-27	9206-9208	of	_
50-28	9209-9212	red	_
50-29	9213-9214	.	_

51-1	9215-9218	The	_
51-2	9219-9229	background	_
51-3	9230-9236	colors	_
51-4	9237-9241	were	_
51-5	9242-9255	approximately	_
51-6	9256-9263	matched	_
51-7	9264-9267	for	_
51-8	9268-9269	a	_
51-9	9270-9278	physical	_
51-10	9279-9288	luminance	_
51-11	9289-9291	of	_
51-12	9292-9294	30	_
51-13	9295-9300	cd/m2	_
51-14	9301-9302	,	_
51-15	9303-9308	using	_
51-16	9309-9310	a	_
51-17	9311-9315	spot	_
51-18	9316-9326	photometer	_
51-19	9327-9333	placed	_
51-20	9334-9336	at	_
51-21	9337-9340	the	_
51-22	9341-9347	center	_
51-23	9348-9350	of	_
51-24	9351-9354	the	_
51-25	9355-9361	screen	_
51-26	9362-9363	.	_

52-1	9364-9367	The	_
52-2	9368-9372	gray	_
52-3	9373-9379	checks	_
52-4	9380-9384	were	_
52-5	9385-9393	brighter	_
52-6	9394-9398	than	_
52-7	9399-9402	the	_
52-8	9403-9413	background	_
52-9	9414-9416	to	_
52-10	9417-9423	create	_
52-11	9424-9427	low	_
52-12	9428-9429	(	_
52-13	9430-9431	8	_
52-14	9432-9433	%	_
52-15	9434-9435	)	_
52-16	9436-9439	and	_
52-17	9440-9444	high	_
52-18	9445-9446	(	_
52-19	9447-9449	64	_
52-20	9450-9451	%	_
52-21	9452-9453	)	_
52-22	9454-9462	contrast	_
52-23	9463-9470	stimuli	_
52-24	9471-9474	for	_
52-25	9475-9479	each	_
52-26	9480-9482	of	_
52-27	9483-9486	the	_
52-28	9487-9492	three	_
52-29	9493-9498	color	_
52-30	9499-9510	backgrounds	_
52-31	9511-9512	.	_

53-1	9513-9516	The	_
53-2	9517-9524	ambient	_
53-3	9525-9530	light	_
53-4	9531-9533	in	_
53-5	9534-9537	the	_
53-6	9538-9542	room	_
53-7	9543-9546	was	_
53-8	9547-9550	dim	_
53-9	9551-9552	(	_
53-10	9553-9566	approximately	_
53-11	9567-9571	0.23	_
53-12	9572-9577	cd/m2	_
53-13	9578-9579	)	_
53-14	9580-9581	.	_

54-1	9582-9585	The	_
54-2	9586-9591	three	_
54-3	9592-9597	color	_
54-4	9598-9609	backgrounds	_
54-5	9610-9616	cycled	_
54-6	9617-9619	in	_
54-7	9620-9626	blocks	_
54-8	9627-9628	,	_
54-9	9629-9633	with	_
54-10	9634-9646	participants	_
54-11	9647-9655	randomly	_
54-12	9656-9664	assigned	_
54-13	9665-9667	to	_
54-14	9668-9671	the	_
54-15	9672-9677	order	_
54-16	9678-9680	of	_
54-17	9681-9695	green–gray–red	_
54-18	9696-9698	or	_
54-19	9699-9713	red–gray–green	_
54-20	9714-9715	.	_

55-1	9716-9720	Each	_
55-2	9721-9723	of	_
55-3	9724-9729	these	_
55-4	9730-9739	sequences	_
55-5	9740-9749	contained	_
55-6	9750-9751	a	_
55-7	9752-9754	20	_
55-8	9755-9761	second	_
55-9	9762-9771	countdown	_
55-10	9772-9776	rest	_
55-11	9777-9783	period	_
55-12	9784-9786	on	_
55-13	9787-9788	a	_
55-14	9789-9794	black	_
55-15	9795-9805	background	_
55-16	9806-9815	following	_
55-17	9816-9820	each	_
55-18	9821-9826	color	_
55-19	9827-9832	block	_
55-20	9833-9834	.	_

56-1	9835-9839	Each	_
56-2	9840-9845	color	_
56-3	9846-9851	block	_
56-4	9852-9861	contained	_
56-5	9862-9864	50	_
56-6	9865-9871	trials	_
56-7	9872-9874	of	_
56-8	9875-9879	each	_
56-9	9880-9882	of	_
56-10	9883-9886	the	_
56-11	9887-9890	two	_
56-12	9891-9900	contrasts	_
56-13	9901-9910	presented	_
56-14	9911-9913	in	_
56-15	9914-9915	a	_
56-16	9916-9922	random	_
56-17	9923-9928	order	_
56-18	9929-9930	.	_

57-1	9931-9934	The	_
57-2	9935-9940	color	_
57-3	9941-9947	blocks	_
57-4	9948-9954	cycled	_
57-5	9955-9959	five	_
57-6	9960-9965	times	_
57-7	9966-9967	,	_
57-8	9968-9977	resulting	_
57-9	9978-9980	in	_
57-10	9981-9984	250	_
57-11	9985-9991	trials	_
57-12	9992-9994	of	_
57-13	9995-9999	each	_
57-14	10000-10008	contrast	_
57-15	10009-10011	by	_
57-16	10012-10017	color	_
57-17	10018-10027	condition	_
57-18	10028-10029	.	_

58-1	10030-10032	In	_
58-2	10033-10041	addition	_
58-3	10042-10043	,	_
58-4	10044-10048	line	_
58-5	10049-10057	drawings	_
58-6	10058-10060	of	_
58-7	10061-10065	four	_
58-8	10066-10075	different	_
58-9	10076-10083	animals	_
58-10	10084-10088	were	_
58-11	10089-10098	presented	_
58-12	10099-10105	during	_
58-13	10106-10108	26	_
58-14	10109-10115	random	_
58-15	10116-10122	trials	_
58-16	10123-10129	within	_
58-17	10130-10134	each	_
58-18	10135-10140	color	_
58-19	10141-10146	block	_
58-20	10147-10148	,	_
58-21	10149-10153	with	_
58-22	10154-10156	13	_
58-23	10157-10159	of	_
58-24	10160-10165	those	_
58-25	10166-10172	trials	_
58-26	10173-10185	representing	_
58-27	10186-10187	a	_
58-28	10188-10194	target	_
58-29	10195-10201	animal	_
58-30	10202-10205	for	_
58-31	10206-10211	which	_
58-32	10212-10215	the	_
58-33	10216-10227	participant	_
58-34	10228-10231	was	_
58-35	10232-10237	asked	_
58-36	10238-10240	to	_
58-37	10241-10246	press	_
58-38	10247-10248	a	_
58-39	10249-10255	button	_
58-40	10256-10258	on	_
58-41	10259-10260	a	_
58-42	10261-10265	game	_
58-43	10266-10276	controller	_
58-44	10277-10278	.	_

59-1	10279-10284	These	_
59-2	10285-10291	animal	_
59-3	10292-10299	stimuli	_
59-4	10300-10304	were	_
59-5	10305-10313	included	_
59-6	10314-10316	to	_
59-7	10317-10321	help	_
59-8	10322-10334	participants	_
59-9	10335-10341	engage	_
59-10	10342-10345	and	_
59-11	10346-10352	attend	_
59-12	10353-10355	to	_
59-13	10356-10359	the	_
59-14	10360-10367	passive	_
59-15	10368-10372	task	_
59-16	10373-10374	–	_
59-17	10375-10385	consistent	_
59-18	10386-10390	with	_
59-19	10391-10395	past	_
59-20	10396-10403	studies	_
59-21	10404-10409	using	_
59-22	10410-10415	check	_
59-23	10416-10422	arrays	_
59-24	10423-10424	.	_

60-1	10425-10429	Each	_
60-2	10430-10438	stimulus	_
60-3	10439-10442	was	_
60-4	10443-10452	presented	_
60-5	10453-10456	for	_
60-6	10457-10459	60	_
60-7	10460-10462	ms	_
60-8	10463-10471	followed	_
60-9	10472-10474	by	_
60-10	10475-10476	a	_
60-11	10477-10482	blank	_
60-12	10483-10489	screen	_
60-13	10490-10492	of	_
60-14	10493-10496	the	_
60-15	10497-10501	same	_
60-16	10502-10507	color	_
60-17	10508-10518	background	_
60-18	10519-10522	for	_
60-19	10523-10525	an	_
60-20	10526-10539	interstimulus	_
60-21	10540-10548	interval	_
60-22	10549-10550	(	_
60-23	10551-10554	ISI	_
60-24	10555-10556	)	_
60-25	10557-10561	that	_
60-26	10562-10568	varied	_
60-27	10569-10577	randomly	_
60-28	10578-10585	between	_
60-29	10586-10589	540	_
60-30	10590-10591	–	_
60-31	10592-10597	1,340	_
60-32	10598-10600	ms	_
60-33	10601-10604	for	_
60-34	10605-10608	the	_
60-35	10609-10617	majority	_
60-36	10618-10620	of	_
60-37	10621-10624	the	_
60-38	10625-10631	trials	_
60-39	10632-10633	,	_
60-40	10634-10642	although	_
60-41	10643-10645	it	_
60-42	10646-10651	could	_
60-43	10652-10658	remain	_
60-44	10659-10661	up	_
60-45	10662-10664	to	_
60-46	10665-10670	5,840	_
60-47	10671-10673	ms	_
60-48	10674-10676	if	_
60-49	10677-10680	the	_
60-50	10681-10684	eye	_
60-51	10685-10692	tracker	_
60-52	10693-10696	did	_
60-53	10697-10700	not	_
60-54	10701-10707	detect	_
60-55	10708-10709	a	_
60-56	10710-10718	fixation	_
60-57	10719-10723	near	_
60-58	10724-10730	center	_
60-59	10731-10733	of	_
60-60	10734-10737	the	_
60-61	10738-10744	screen	_
60-62	10745-10746	(	_
60-63	10747-10754	details	_
60-64	10755-10763	provided	_
60-65	10764-10769	below	_
60-66	10770-10771	)	_
60-67	10772-10773	.	_

61-1	10774-10777	The	_
61-2	10778-10786	duration	_
61-3	10787-10789	of	_
61-4	10790-10793	the	_
61-5	10794-10800	entire	_
61-6	10801-10805	task	_
61-7	10806-10809	was	_
61-8	10810-10823	approximately	_
61-9	10824-10826	50	_
61-10	10827-10834	minutes	_
61-11	10835-10836	.	_

62-1	10837-10838	A	_
62-2	10839-10846	graphic	_
62-3	10847-10861	representation	_
62-4	10862-10864	of	_
62-5	10865-10869	task	_
62-6	10870-10874	flow	_
62-7	10875-10877	is	_
62-8	10878-10886	provided	_
62-9	10887-10889	in	_
62-10	10890-10896	Figure	_
62-11	10897-10898	6	_
62-12	10899-10900	.	_

63-1	10901-10904	EEG	http://maven.renci.org/NeuroBridge/neurobridge#Electroencephalogram
63-2	10905-10908	was	_
63-3	10909-10917	recorded	_
63-4	10918-10923	using	_
63-5	10924-10925	a	_
63-6	10926-10928	64	_
63-7	10929-10936	channel	_
63-8	10937-10946	Neuroscan	_
63-9	10947-10955	Synamps2	_
63-10	10956-10962	system	http://maven.renci.org/NeuroBridge/neurobridge#ReproductiveDisease
63-11	10963-10964	,	_
63-12	10965-10969	with	_
63-13	10970-10972	DC	_
63-14	10973-10982	recording	_
63-15	10983-10992	digitized	_
63-16	10993-10995	at	_
63-17	10996-11001	1,000	_
63-18	11002-11004	Hz	_
63-19	11005-11006	,	_
63-20	11007-11011	with	_
63-21	11012-11013	a	_
63-22	11014-11017	200	_
63-23	11018-11020	Hz	_
63-24	11021-11024	low	_
63-25	11025-11029	pass	_
63-26	11030-11036	filter	_
63-27	11037-11038	,	_
63-28	11039-11041	no	_
63-29	11042-11051	high-pass	_
63-30	11052-11058	filter	_
63-31	11059-11060	,	_
63-32	11061-11064	and	_
63-33	11065-11074	impedance	_
63-34	11075-11077	of	_
63-35	11078-11082	less	_
63-36	11083-11087	than	_
63-37	11088-11090	10	_
63-38	11091-11096	kOhms	_
63-39	11097-11099	at	_
63-40	11100-11104	each	_
63-41	11105-11114	electrode	_
63-42	11115-11116	.	_

64-1	11117-11120	The	_
64-2	11121-11128	average	_
64-3	11129-11133	from	_
64-4	11134-11142	unlinked	_
64-5	11143-11152	bilateral	_
64-6	11153-11160	mastoid	_
64-7	11161-11171	electrodes	_
64-8	11172-11176	were	_
64-9	11177-11181	used	_
64-10	11182-11184	as	_
64-11	11185-11188	the	_
64-12	11189-11195	active	_
64-13	11196-11205	reference	_
64-14	11206-11207	,	_
64-15	11208-11211	and	_
64-16	11212-11220	vertical	_
64-17	11221-11224	and	_
64-18	11225-11235	horizontal	_
64-19	11236-11242	ocular	_
64-20	11243-11253	electrodes	_
64-21	11254-11258	were	_
64-22	11259-11263	used	_
64-23	11264-11266	to	_
64-24	11267-11275	estimate	_
64-25	11276-11282	blinks	_
64-26	11283-11286	and	_
64-27	11287-11292	large	_
64-28	11293-11296	eye	_
64-29	11297-11306	movements	_
64-30	11307-11308	.	_

65-1	11309-11312	Eye	_
65-2	11313-11322	movements	_
65-3	11323-11327	were	_
65-4	11328-11336	recorded	_
65-5	11337-11348	monocularly	_
65-6	11349-11353	from	_
65-7	11354-11357	the	_
65-8	11358-11363	right	_
65-9	11364-11367	eye	_
65-10	11368-11373	using	_
65-11	11374-11376	an	_
65-12	11377-11384	EyeLink	_
65-13	11385-11389	1000	_
65-14	11390-11396	remote	_
65-15	11397-11400	eye	_
65-16	11401-11408	tracker	_
65-17	11409-11410	(	_
65-18	11411-11413	SR	_
65-19	11414-11422	Research	_
65-20	11423-11427	Ltd.	_
65-21	11428-11429	,	_
65-22	11430-11442	Mississsauga	_
65-23	11443-11444	,	_
65-24	11445-11452	Ontario	_
65-25	11453-11454	,	_
65-26	11455-11461	Canada	_
65-27	11462-11463	)	_
65-28	11464-11465	,	_
65-29	11466-11474	sampling	_
65-30	11475-11477	at	_
65-31	11478-11481	500	_
65-32	11482-11484	Hz	_
65-33	11485-11486	.	_

66-1	11487-11490	The	_
66-2	11491-11495	task	_
66-3	11496-11501	began	_
66-4	11502-11506	with	_
66-5	11507-11508	a	_
66-6	11509-11519	five-point	_
66-7	11520-11531	calibration	_
66-8	11532-11539	routine	_
66-9	11540-11542	to	_
66-10	11543-11546	set	_
66-11	11547-11550	the	_
66-12	11551-11558	average	_
66-13	11559-11562	and	_
66-14	11563-11570	maximum	_
66-15	11571-11582	calibration	_
66-16	11583-11588	error	_
66-17	11589-11591	at	_
66-18	11592-11596	less	_
66-19	11597-11601	than	_
66-20	11602-11606	0.5°	_
66-21	11607-11610	and	_
66-22	11611-11615	1.0°	_
66-23	11616-11618	of	_
66-24	11619-11625	visual	_
66-25	11626-11631	angle	_
66-26	11632-11644	respectively	_
66-27	11645-11646	.	_

67-1	11647-11656	Following	_
67-2	11657-11661	each	_
67-3	11662-11670	stimulus	_
67-4	11671-11674	and	_
67-5	11675-11677	an	_
67-6	11678-11685	initial	_
67-7	11686-11694	randomly	_
67-8	11695-11703	selected	_
67-9	11704-11707	ISI	_
67-10	11708-11710	of	_
67-11	11711-11713	40	_
67-12	11714-11716	to	_
67-13	11717-11720	840	_
67-14	11721-11723	ms	_
67-15	11724-11725	,	_
67-16	11726-11729	the	_
67-17	11730-11733	eye	_
67-18	11734-11741	tracker	_
67-19	11742-11751	monitored	_
67-20	11752-11755	for	_
67-21	11756-11757	a	_
67-22	11758-11766	fixation	_
67-23	11767-11769	of	_
67-24	11770-11772	at	_
67-25	11773-11778	least	_
67-26	11779-11782	500	_
67-27	11783-11785	ms	_
67-28	11786-11788	in	_
67-29	11789-11792	the	_
67-30	11793-11799	center	_
67-31	11800-11802	of	_
67-32	11803-11806	the	_
67-33	11807-11813	screen	_
67-34	11814-11815	(	_
67-35	11816-11818	7°	_
67-36	11819-11820	×	_
67-37	11821-11823	7°	_
67-38	11824-11830	visual	_
67-39	11831-11836	angle	_
67-40	11837-11838	)	_
67-41	11839-11840	,	_
67-42	11841-11846	which	_
67-43	11847-11852	would	_
67-44	11853-11857	then	_
67-45	11858-11865	trigger	_
67-46	11866-11869	the	_
67-47	11870-11882	presentation	_
67-48	11883-11885	of	_
67-49	11886-11889	the	_
67-50	11890-11894	next	_
67-51	11895-11903	stimulus	_
67-52	11904-11905	.	_

68-1	11906-11910	This	_
68-2	11911-11917	helped	_
68-3	11918-11924	ensure	_
68-4	11925-11929	that	_
68-5	11930-11942	participants	_
68-6	11943-11946	had	_
68-7	11947-11952	their	_
68-8	11953-11957	eyes	_
68-9	11958-11962	open	_
68-10	11963-11966	and	_
68-11	11967-11974	fixated	_
68-12	11975-11979	near	_
68-13	11980-11983	the	_
68-14	11984-11990	center	_
68-15	11991-11993	of	_
68-16	11994-11997	the	_
68-17	11998-12004	screen	_
68-18	12005-12016	immediately	_
68-19	12017-12022	prior	_
68-20	12023-12025	to	_
68-21	12026-12029	the	_
68-22	12030-12042	presentation	_
68-23	12043-12045	of	_
68-24	12046-12050	each	_
68-25	12051-12059	stimulus	_
68-26	12060-12061	.	_

69-1	12062-12064	If	_
69-2	12065-12066	a	_
69-3	12067-12079	sufficiently	_
69-4	12080-12084	long	_
69-5	12085-12092	central	_
69-6	12093-12101	fixation	_
69-7	12102-12105	was	_
69-8	12106-12109	not	_
69-9	12110-12118	detected	_
69-10	12119-12125	within	_
69-11	12126-12131	5,000	_
69-12	12132-12134	ms	_
69-13	12135-12136	,	_
69-14	12137-12140	the	_
69-15	12141-12144	eye	_
69-16	12145-12152	tracker	_
69-17	12153-12161	recorded	_
69-18	12162-12166	that	_
69-19	12167-12170	the	_
69-20	12171-12174	ISI	_
69-21	12175-12178	had	_
69-22	12179-12184	timed	_
69-23	12185-12188	out	_
69-24	12189-12192	and	_
69-25	12193-12202	proceeded	_
69-26	12203-12205	to	_
69-27	12206-12209	the	_
69-28	12210-12214	next	_
69-29	12215-12220	trial	_
69-30	12221-12222	.	_

70-1	12223-12227	This	_
70-2	12228-12237	procedure	_
70-3	12238-12246	resulted	_
70-4	12247-12249	in	_
70-5	12250-12251	a	_
70-6	12252-12257	total	_
70-7	12258-12266	possible	_
70-8	12267-12270	ISI	_
70-9	12271-12279	duration	_
70-10	12280-12282	of	_
70-11	12283-12286	540	_
70-12	12287-12293	-5,840	_
70-13	12294-12297	ms.	_
70-14	12298-12303	4.2.3	_
70-15	12304-12305	.	_

71-1	12306-12309	VEP	_
71-2	12310-12321	Measurement	_
71-3	12322-12332	Procedures	_
71-4	12333-12336	The	_
71-5	12337-12340	VEP	_
71-6	12341-12345	data	_
71-7	12346-12349	was	_
71-8	12350-12358	analyzed	_
71-9	12359-12364	using	_
71-10	12365-12370	Brain	_
71-11	12371-12377	Vision	_
71-12	12378-12386	Analyzer	_
71-13	12387-12392	2.1.2	_
71-14	12393-12401	software	_
71-15	12402-12405	and	_
71-16	12406-12409	was	_
71-17	12410-12418	filtered	_
71-18	12419-12426	offline	_
71-19	12427-12432	using	_
71-20	12433-12434	a	_
71-21	12435-12439	high	_
71-22	12440-12444	pass	_
71-23	12445-12451	filter	_
71-24	12452-12454	of	_
71-25	12455-12459	0.10	_
71-26	12460-12462	Hz	_
71-27	12463-12466	and	_
71-28	12467-12470	low	_
71-29	12471-12475	pass	_
71-30	12476-12482	filter	_
71-31	12483-12485	of	_
71-32	12486-12488	45	_
71-33	12489-12491	Hz	_
71-34	12492-12493	,	_
71-35	12494-12498	both	_
71-36	12499-12504	using	_
71-37	12505-12506	a	_
71-38	12507-12511	roll	_
71-39	12512-12515	off	_
71-40	12516-12518	of	_
71-41	12519-12521	48	_
71-42	12522-12528	db/oct	_
71-43	12529-12530	.	_

72-1	12531-12534	The	_
72-2	12535-12539	data	_
72-3	12540-12543	was	_
72-4	12544-12553	segmented	_
72-5	12554-12558	from	_
72-6	12559-12563	-100	_
72-7	12564-12566	to	_
72-8	12567-12570	500	_
72-9	12571-12573	ms	_
72-10	12574-12579	based	_
72-11	12580-12582	on	_
72-12	12583-12586	the	_
72-13	12587-12592	onset	_
72-14	12593-12595	of	_
72-15	12596-12599	the	_
72-16	12600-12605	check	_
72-17	12606-12613	stimuli	_
72-18	12614-12615	(	_
72-19	12616-12631	stimulus-locked	_
72-20	12632-12633	)	_
72-21	12634-12635	,	_
72-22	12636-12639	and	_
72-23	12640-12643	was	_
72-24	12644-12648	then	_
72-25	12649-12658	corrected	_
72-26	12659-12662	for	_
72-27	12663-12669	blinks	_
72-28	12670-12673	and	_
72-29	12674-12679	large	_
72-30	12680-12683	eye	_
72-31	12684-12693	movements	_
72-32	12694-12699	using	_
72-33	12700-12711	independent	_
72-34	12712-12721	component	_
72-35	12722-12730	analysis	_
72-36	12731-12733	on	_
72-37	12734-12737	the	_
72-38	12738-12744	ocular	_
72-39	12745-12755	electrodes	_
72-40	12756-12757	.	_

73-1	12758-12762	Data	_
73-2	12763-12767	were	_
73-3	12768-12780	down-sampled	_
73-4	12781-12783	to	_
73-5	12784-12787	500	_
73-6	12788-12790	Hz	_
73-7	12791-12792	,	_
73-8	12793-12806	re-referenced	_
73-9	12807-12809	to	_
73-10	12810-12813	the	_
73-11	12814-12820	common	_
73-12	12821-12828	average	_
73-13	12829-12830	,	_
73-14	12831-12834	and	_
73-15	12835-12843	baseline	_
73-16	12844-12853	corrected	_
73-17	12854-12858	from	_
73-18	12859-12863	-100	_
73-19	12864-12866	to	_
73-20	12867-12868	0	_
73-21	12869-12872	ms.	_
73-22	12873-12881	Artifact	_
73-23	12882-12891	rejection	_
73-24	12892-12899	removed	_
73-25	12900-12908	segments	_
73-26	12909-12913	from	_
73-27	12914-12924	particular	_
73-28	12925-12935	electrodes	_
73-29	12936-12946	containing	_
73-30	12947-12951	more	_
73-31	12952-12956	than	_
73-32	12957-12958	a	_
73-33	12959-12962	+/-	_
73-34	12963-12966	100	_
73-35	12967-12969	μV	_
73-36	12970-12980	deflection	_
73-37	12981-12982	.	_

74-1	12983-12985	We	_
74-2	12986-12990	then	_
74-3	12991-13000	segmented	_
74-4	13001-13004	the	_
74-5	13005-13009	data	_
74-6	13010-13015	based	_
74-7	13016-13018	on	_
74-8	13019-13022	the	_
74-9	13023-13031	contrast	_
74-10	13032-13035	and	_
74-11	13036-13041	color	_
74-12	13042-13051	condition	_
74-13	13052-13055	and	_
74-14	13056-13064	averaged	_
74-15	13065-13068	the	_
74-16	13069-13077	segments	_
74-17	13078-13084	within	_
74-18	13085-13089	each	_
74-19	13090-13099	condition	_
74-20	13100-13105	using	_
74-21	13106-13116	individual	_
74-22	13117-13124	channel	_
74-23	13125-13129	mode	_
74-24	13130-13131	.	_

75-1	13132-13137	Brain	_
75-2	13138-13146	electric	_
75-3	13147-13153	source	_
75-4	13154-13162	analysis	_
75-5	13163-13164	(	_
75-6	13165-13169	BESA	_
75-7	13170-13171	)	_
75-8	13172-13175	The	_
75-9	13176-13181	basic	_
75-10	13182-13189	premise	_
75-11	13190-13192	of	_
75-12	13193-13199	source	_
75-13	13200-13208	modeling	_
75-14	13209-13211	is	_
75-15	13212-13216	that	_
75-16	13217-13218	a	_
75-17	13219-13228	component	_
75-18	13229-13232	can	_
75-19	13233-13235	be	_
75-20	13236-13243	defined	_
75-21	13244-13246	as	_
75-22	13247-13250	the	_
75-23	13251-13255	part	_
75-24	13256-13258	of	_
75-25	13259-13262	the	_
75-26	13263-13268	scalp	_
75-27	13269-13277	waveform	_
75-28	13278-13282	that	_
75-29	13283-13290	results	_
75-30	13291-13295	from	_
75-31	13296-13299	the	_
75-32	13300-13308	compound	_
75-33	13309-13314	local	_
75-34	13315-13323	activity	_
75-35	13324-13326	of	_
75-36	13327-13328	a	_
75-37	13329-13342	circumscribed	_
75-38	13343-13348	brain	_
75-39	13349-13355	region	_
75-40	13356-13357	.	_

76-1	13358-13362	BESA	_
76-2	13363-13370	employs	_
76-3	13371-13372	a	_
76-4	13373-13378	least	_
76-5	13379-13386	squares	_
76-6	13387-13394	fitting	_
76-7	13395-13404	algorithm	_
76-8	13405-13406	,	_
76-9	13407-13411	over	_
76-10	13412-13417	which	_
76-11	13418-13421	the	_
76-12	13422-13426	user	_
76-13	13427-13430	has	_
76-14	13431-13442	interactive	_
76-15	13443-13450	control	_
76-16	13451-13452	.	_

77-1	13453-13459	Source	_
77-2	13460-13472	localization	_
77-3	13473-13481	proceeds	_
77-4	13482-13484	by	_
77-5	13485-13486	a	_
77-6	13487-13493	search	_
77-7	13494-13500	within	_
77-8	13501-13504	the	_
77-9	13505-13509	head	_
77-10	13510-13515	model	_
77-11	13516-13519	for	_
77-12	13520-13521	a	_
77-13	13522-13530	location	_
77-14	13531-13536	where	_
77-15	13537-13540	the	_
77-16	13541-13548	sources	_
77-17	13549-13552	can	_
77-18	13553-13560	explain	_
77-19	13561-13562	a	_
77-20	13563-13570	maximal	_
77-21	13571-13577	amount	_
77-22	13578-13580	of	_
77-23	13581-13589	variance	_
77-24	13590-13591	.	_

78-1	13592-13596	Here	_
78-2	13597-13598	,	_
78-3	13599-13601	we	_
78-4	13602-13609	assumed	_
78-5	13610-13619	bilateral	_
78-6	13620-13631	symmetrical	_
78-7	13632-13639	sources	_
78-8	13640-13641	.	_

79-1	13642-13644	An	_
79-2	13645-13655	assumption	_
79-3	13656-13658	of	_
79-4	13659-13666	spatial	_
79-5	13667-13675	symmetry	_
79-6	13676-13688	considerably	_
79-7	13689-13696	reduces	_
79-8	13697-13700	the	_
79-9	13701-13707	number	_
79-10	13708-13710	of	_
79-11	13711-13722	independent	_
79-12	13723-13733	parameters	_
79-13	13734-13736	to	_
79-14	13737-13739	be	_
79-15	13740-13750	determined	_
79-16	13751-13754	and	_
79-17	13755-13757	is	_
79-18	13758-13768	consistent	_
79-19	13769-13773	with	_
79-20	13774-13777	the	_
79-21	13778-13783	known	_
79-22	13784-13794	generators	_
79-23	13795-13797	of	_
79-24	13798-13800	P1	_
79-25	13801-13802	.	_

80-1	13803-13806	The	_
80-2	13807-13814	inverse	_
80-3	13815-13824	leadfield	_
80-4	13825-13831	matrix	_
80-5	13832-13833	(	_
80-6	13834-13838	i.e.	_
80-7	13839-13840	,	_
80-8	13841-13844	the	_
80-9	13845-13851	matrix	_
80-10	13852-13854	of	_
80-11	13855-13867	coefficients	_
80-12	13868-13872	that	_
80-13	13873-13877	maps	_
80-14	13878-13885	current	_
80-15	13886-13893	sources	_
80-16	13894-13896	to	_
80-17	13897-13904	surface	_
80-18	13905-13915	potentials	_
80-19	13916-13917	)	_
80-20	13918-13921	was	_
80-21	13922-13926	then	_
80-22	13927-13931	used	_
80-23	13932-13934	to	_
80-24	13935-13942	project	_
80-25	13943-13946	the	_
80-26	13947-13954	modeled	_
80-27	13955-13962	dipolar	_
80-28	13963-13971	activity	_
80-29	13972-13976	back	_
80-30	13977-13981	onto	_
80-31	13982-13985	the	_
80-32	13986-13991	scalp	_
80-33	13992-13999	surface	_
80-34	14000-14002	in	_
80-35	14003-14008	order	_
80-36	14009-14011	to	_
80-37	14012-14018	select	_
80-38	14019-14022	the	_
80-39	14023-14030	optimal	_
80-40	14031-14039	channels	_
80-41	14040-14044	used	_
80-42	14045-14048	for	_
80-43	14049-14052	the	_
80-44	14053-14056	ERP	_
80-45	14057-14065	analysis	_
80-46	14066-14068	of	_
80-47	14069-14072	the	_
80-48	14073-14075	P1	_
80-49	14076-14085	component	_
80-50	14086-14087	.	_

81-1	14088-14094	Source	_
81-2	14095-14103	modeling	_
81-3	14104-14112	resulted	_
81-4	14113-14115	in	_
81-5	14116-14123	dipoles	_
81-6	14124-14133	localized	_
81-7	14134-14136	to	_
81-8	14137-14147	generators	_
81-9	14148-14150	in	_
81-10	14151-14157	dorsal	_
81-11	14158-14170	extrastriate	_
81-12	14171-14177	cortex	_
81-13	14178-14180	of	_
81-14	14181-14184	the	_
81-15	14185-14191	middle	_
81-16	14192-14201	occipital	_
81-17	14202-14207	gyrus	_
81-18	14208-14218	consistent	_
81-19	14219-14223	with	_
81-20	14224-14232	previous	_
81-21	14233-14240	studies	_
81-22	14241-14242	.	_

82-1	14243-14246	The	_
82-2	14247-14252	model	_
82-3	14253-14261	produced	_
82-4	14262-14263	a	_
82-5	14264-14279	goodness-of-fit	_
82-6	14280-14285	value	_
82-7	14286-14288	of	_
82-8	14289-14293	96.4	_
82-9	14294-14295	%	_
82-10	14296-14297	(	_
82-11	14298-14306	residual	_
82-12	14307-14315	variance	_
82-13	14316-14317	=	_
82-14	14318-14321	3.6	_
82-15	14322-14323	%	_
82-16	14324-14325	)	_
82-17	14326-14332	across	_
82-18	14333-14336	the	_
82-19	14337-14344	modeled	_
82-20	14345-14350	epoch	_
82-21	14351-14353	of	_
82-22	14354-14356	80	_
82-23	14357-14358	–	_
82-24	14359-14362	116	_
82-25	14363-14365	ms	_
82-26	14366-14367	(	_
82-27	14368-14371	see	_
82-28	14372-14378	Figure	_
82-29	14379-14380	7	_
82-30	14381-14382	a	_
82-31	14383-14384	,	_
82-32	14385-14386	b	_
82-33	14387-14388	)	_
82-34	14389-14390	.	_

83-1	14391-14396	Based	_
83-2	14397-14399	on	_
83-3	14400-14403	the	_
83-4	14404-14416	distribution	_
83-5	14417-14419	of	_
83-6	14420-14423	the	_
83-7	14424-14431	dipolar	_
83-8	14432-14439	surface	_
83-9	14440-14450	projection	_
83-10	14451-14452	,	_
83-11	14453-14455	we	_
83-12	14456-14461	chose	_
83-13	14462-14464	to	_
83-14	14465-14472	measure	_
83-15	14473-14475	P1	_
83-16	14476-14480	from	_
83-17	14481-14484	the	_
83-18	14485-14492	average	_
83-19	14493-14495	of	_
83-20	14496-14499	six	_
83-21	14500-14510	electrodes	_
83-22	14511-14515	from	_
83-23	14516-14520	each	_
83-24	14521-14531	hemisphere	_
83-25	14532-14533	:	_
83-26	14534-14539	TP7/8	_
83-27	14540-14541	,	_
83-28	14542-14547	CP5/6	_
83-29	14548-14549	,	_
83-30	14550-14555	CP3/4	_
83-31	14556-14557	,	_
83-32	14558-14562	P7/8	_
83-33	14563-14564	,	_
83-34	14565-14569	P5/6	_
83-35	14570-14571	,	_
83-36	14572-14575	and	_
83-37	14576-14580	P3/4	_
83-38	14581-14582	,	_
83-39	14583-14593	generating	_
83-40	14594-14597	one	_
83-41	14598-14606	analysis	_
83-42	14607-14613	region	_
83-43	14614-14616	of	_
83-44	14617-14625	interest	_
83-45	14626-14627	(	_
83-46	14628-14631	ROI	_
83-47	14632-14633	)	_
83-48	14634-14636	on	_
83-49	14637-14641	each	_
83-50	14642-14652	hemisphere	_
83-51	14653-14654	(	_
83-52	14655-14658	see	_
83-53	14659-14665	Figure	_
83-54	14666-14668	7c	_
83-55	14669-14670	)	_
83-56	14671-14672	.	_

84-1	14673-14675	We	_
84-2	14676-14684	measured	_
84-3	14685-14687	P1	_
84-4	14688-14698	separately	_
84-5	14699-14702	for	_
84-6	14703-14707	each	_
84-7	14708-14711	ROI	_
84-8	14712-14713	,	_
84-9	14714-14719	using	_
84-10	14720-14723	the	_
84-11	14724-14731	largest	_
84-12	14732-14740	positive	_
84-13	14741-14745	peak	_
84-14	14746-14755	appearing	_
84-15	14756-14758	in	_
84-16	14759-14762	the	_
84-17	14763-14767	time	_
84-18	14768-14774	window	_
84-19	14775-14777	of	_
84-20	14778-14780	60	_
84-21	14781-14783	to	_
84-22	14784-14787	195	_
84-23	14788-14790	ms	_
84-24	14791-14792	.	_

85-1	14793-14796	The	_
85-2	14797-14804	average	_
85-3	14805-14814	amplitude	_
85-4	14815-14817	of	_
85-5	14818-14822	this	_
85-6	14823-14827	peak	_
85-7	14828-14831	was	_
85-8	14832-14840	measured	_
85-9	14841-14846	using	_
85-10	14847-14848	a	_
85-11	14849-14851	20	_
85-12	14852-14854	ms	_
85-13	14855-14861	window	_
85-14	14862-14870	centered	_
85-15	14871-14873	on	_
85-16	14874-14877	the	_
85-17	14878-14882	peak	_
85-18	14883-14887	from	_
85-19	14888-14891	the	_
85-20	14892-14900	averaged	_
85-21	14901-14909	waveform	_
85-22	14910-14913	for	_
85-23	14914-14918	each	_
85-24	14919-14929	hemisphere	_
85-25	14930-14933	and	_
85-26	14934-14943	condition	_
85-27	14944-14950	within	_
85-28	14951-14955	each	_
85-29	14956-14967	participant	_
85-30	14968-14969	.	_

86-1	14970-14973	See	_
86-2	14974-14980	Figure	_
86-3	14981-14982	8	_
86-4	14983-14986	for	_
86-5	14987-14988	a	_
86-6	14989-14998	depiction	_
86-7	14999-15001	of	_
86-8	15002-15005	the	_
86-9	15006-15011	grand	_
86-10	15012-15019	average	_
86-11	15020-15029	waveforms	_
86-12	15030-15032	by	_
86-13	15033-15038	color	_
86-14	15039-15042	and	_
86-15	15043-15051	contrast	_
86-16	15052-15058	across	_
86-17	15059-15062	all	_
86-18	15063-15075	participants	_
86-19	15076-15077	.	_

87-1	15078-15081	4.3	_
87-2	15082-15083	.	_

88-1	15084-15095	Statistical	_
88-2	15096-15104	Analyses	_
88-3	15105-15110	Prior	_
88-4	15111-15113	to	_
88-5	15114-15123	examining	_
88-6	15124-15131	symptom	_
88-7	15132-15145	relationships	_
88-8	15146-15147	,	_
88-9	15148-15150	we	_
88-10	15151-15159	examined	_
88-11	15160-15162	P1	_
88-12	15163-15172	amplitude	_
88-13	15173-15179	across	_
88-14	15180-15183	the	_
88-15	15184-15190	entire	_
88-16	15191-15197	sample	_
88-17	15198-15203	using	_
88-18	15204-15221	repeated-measures	_
88-19	15222-15229	ANCOVAs	_
88-20	15230-15232	to	_
88-21	15233-15239	assess	_
88-22	15240-15243	the	_
88-23	15244-15251	general	_
88-24	15252-15259	effects	_
88-25	15260-15262	of	_
88-26	15263-15271	contrast	_
88-27	15272-15275	and	_
88-28	15276-15286	hemisphere	_
88-29	15287-15288	.	_

89-1	15289-15292	For	_
89-2	15293-15304	examination	_
89-3	15305-15307	of	_
89-4	15308-15315	symptom	_
89-5	15316-15329	relationships	_
89-6	15330-15334	with	_
89-7	15335-15338	the	_
89-8	15339-15341	P1	_
89-9	15342-15351	amplitude	_
89-10	15352-15353	,	_
89-11	15354-15356	we	_
89-12	15357-15366	conducted	_
89-13	15367-15373	linear	_
89-14	15374-15385	regressions	_
89-15	15386-15387	,	_
89-16	15388-15392	with	_
89-17	15393-15405	hypothesized	_
89-18	15406-15414	symptoms	_
89-19	15415-15422	entered	_
89-20	15423-15437	simultaneously	_
89-21	15438-15439	.	_

90-1	15440-15442	As	_
90-2	15443-15448	there	_
90-3	15449-15452	was	_
90-4	15453-15464	substantial	_
90-5	15465-15471	shared	_
90-6	15472-15480	variance	_
90-7	15481-15488	between	_
90-8	15489-15504	clinician-rated	_
90-9	15505-15508	and	_
90-10	15509-15522	self-reported	_
90-11	15523-15531	symptoms	_
90-12	15532-15533	,	_
90-13	15534-15536	we	_
90-14	15537-15540	ran	_
90-15	15541-15549	separate	_
90-16	15550-15561	regressions	_
90-17	15562-15565	for	_
90-18	15566-15570	each	_
90-19	15571-15575	type	_
90-20	15576-15578	of	_
90-21	15579-15589	assessment	_
90-22	15590-15598	modality	_
90-23	15599-15600	.	_

91-1	15601-15609	Analyses	_
91-2	15610-15614	with	_
91-3	15615-15618	the	_
91-4	15619-15623	gray	_
91-5	15624-15634	background	_
91-6	15635-15643	included	_
91-7	15644-15647	the	_
91-8	15648-15651	two	_
91-9	15652-15664	hypothesized	_
91-10	15665-15680	clinician-rated	_
91-11	15681-15686	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
91-12	15687-15695	symptoms	_
91-13	15696-15698	of	_
91-14	15699-15708	Delusions	_
91-15	15709-15710	(	_
91-16	15711-15713	P1	_
91-17	15714-15715	)	_
91-18	15716-15719	and	_
91-19	15720-15730	Conceptual	_
91-20	15731-15746	Disorganization	_
91-21	15747-15748	(	_
91-22	15749-15751	P2	_
91-23	15752-15753	)	_
91-24	15754-15755	,	_
91-25	15756-15761	along	_
91-26	15762-15766	with	_
91-27	15767-15770	two	_
91-28	15771-15776	other	_
91-29	15777-15785	symptoms	_
91-30	15786-15791	found	_
91-31	15792-15794	in	_
91-32	15795-15796	a	_
91-33	15797-15803	single	_
91-34	15804-15808	past	_
91-35	15809-15814	study	_
91-36	15815-15816	-	_
91-37	15817-15843	Suspiciousness/Persecution	_
91-38	15844-15845	(	_
91-39	15846-15848	P6	_
91-40	15849-15850	)	_
91-41	15851-15852	,	_
91-42	15853-15856	and	_
91-43	15857-15866	Emotional	_
91-44	15867-15877	Withdrawal	_
91-45	15878-15879	(	_
91-46	15880-15882	N2	_
91-47	15883-15884	)	_
91-48	15885-15886	,	_
91-49	15887-15890	and	_
91-50	15891-15904	corresponding	_
91-51	15905-15918	self-reported	_
91-52	15919-15927	symptoms	_
91-53	15928-15932	from	_
91-54	15933-15936	the	_
91-55	15937-15943	SPQ-BR	_
91-56	15944-15953	subscales	_
91-57	15954-15956	of	_
91-58	15957-15958	:	_
91-59	15959-15966	Magical	_
91-60	15967-15975	Thinking	_
91-61	15976-15977	,	_
91-62	15978-15987	Eccentric	_
91-63	15988-15996	Behavior	_
91-64	15997-15998	,	_
91-65	15999-16002	Odd	_
91-66	16003-16009	Speech	_
91-67	16010-16011	,	_
91-68	16012-16015	and	_
91-69	16016-16030	Suspiciousness	_
91-70	16031-16032	(	_
91-71	16033-16036	sum	_
91-72	16037-16039	of	_
91-73	16040-16043	the	_
91-74	16044-16049	three	_
91-75	16050-16055	items	_
91-76	16056-16057	;	_
91-77	16058-16067	excluding	_
91-78	16068-16073	Ideas	_
91-79	16074-16076	of	_
91-80	16077-16086	Reference	_
91-81	16087-16092	items	_
91-82	16093-16094	)	_
91-83	16095-16096	.	_

92-1	16097-16105	Analyses	_
92-2	16106-16115	examining	_
92-3	16116-16119	the	_
92-4	16120-16126	change	_
92-5	16127-16131	from	_
92-6	16132-16135	the	_
92-7	16136-16141	green	_
92-8	16142-16144	to	_
92-9	16145-16148	red	_
92-10	16149-16159	background	_
92-11	16160-16168	included	_
92-12	16169-16172	the	_
92-13	16173-16176	two	_
92-14	16177-16189	hypothesized	_
92-15	16190-16195	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
92-16	16196-16204	symptoms	_
92-17	16205-16207	of	_
92-18	16208-16215	Blunted	_
92-19	16216-16222	Affect	_
92-20	16223-16224	(	_
92-21	16225-16227	N1	_
92-22	16228-16229	)	_
92-23	16230-16233	and	_
92-24	16234-16251	Passive/Apathetic	_
92-25	16252-16258	Social	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
92-26	16259-16269	Withdrawal	http://maven.renci.org/NeuroBridge/neurobridge#WisconsinSmokingWithdrawalScale
92-27	16270-16271	(	_
92-28	16272-16274	N4	_
92-29	16275-16276	)	_
92-30	16277-16278	,	_
92-31	16279-16282	and	_
92-32	16283-16290	related	_
92-33	16291-16302	self-report	_
92-34	16303-16309	scales	_
92-35	16310-16312	of	_
92-36	16313-16319	SPQ-BR	_
92-37	16320-16331	Constricted	_
92-38	16332-16338	Affect	_
92-39	16339-16340	(	_
92-40	16341-16344	sum	_
92-41	16345-16347	of	_
92-42	16348-16351	the	_
92-43	16352-16357	three	_
92-44	16358-16363	items	_
92-45	16364-16365	;	_
92-46	16366-16375	excluding	_
92-47	16376-16378	No	_
92-48	16379-16384	Close	_
92-49	16385-16392	Friends	_
92-50	16393-16398	items	_
92-51	16399-16400	)	_
92-52	16401-16402	,	_
92-53	16403-16409	SPQ-BR	_
92-54	16410-16416	Social	_
92-55	16417-16424	Anxiety	_
92-56	16425-16426	,	_
92-57	16427-16430	and	_
92-58	16431-16434	the	_
92-59	16435-16440	ACIPS	_
92-60	16441-16446	total	_
92-61	16447-16452	score	_
92-62	16453-16454	.	_

93-1	16455-16457	We	_
93-2	16458-16462	also	_
93-3	16463-16468	added	_
93-4	16469-16475	SPQ-BR	_
93-5	16476-16481	Ideas	_
93-6	16482-16484	of	_
93-7	16485-16494	Reference	_
93-8	16495-16496	(	_
93-9	16497-16500	sum	_
93-10	16501-16503	of	_
93-11	16504-16507	the	_
93-12	16508-16513	three	_
93-13	16514-16519	items	_
93-14	16520-16521	;	_
93-15	16522-16531	excluding	_
93-16	16532-16546	Suspiciousness	_
93-17	16547-16552	items	_
93-18	16553-16554	)	_
93-19	16555-16558	and	_
93-20	16559-16562	the	_
93-21	16563-16576	corresponding	_
93-22	16577-16582	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
93-23	16583-16592	Delusions	_
93-24	16593-16597	item	_
93-25	16598-16600	to	_
93-26	16601-16609	analyses	_
93-27	16610-16612	as	_
93-28	16613-16616	one	_
93-29	16617-16621	past	_
93-30	16622-16627	study	_
93-31	16628-16633	using	_
93-32	16634-16637	the	_
93-33	16638-16642	full	_
93-34	16643-16651	original	_
93-35	16652-16655	SPQ	_
93-36	16656-16661	found	_
93-37	16662-16666	this	_
93-38	16667-16678	association	_
93-39	16679-16680	.	_

94-1	16681-16684	Any	_
94-2	16685-16698	statistically	_
94-3	16699-16710	significant	_
94-4	16711-16722	regressions	_
94-5	16723-16727	were	_
94-6	16728-16732	then	_
94-7	16733-16741	repeated	_
94-8	16742-16746	with	_
94-9	16747-16750	the	_
94-10	16751-16759	addition	_
94-11	16760-16762	of	_
94-12	16763-16772	covarying	_
94-13	16773-16776	for	_
94-14	16777-16787	diagnostic	_
94-15	16788-16793	class	_
94-16	16794-16796	in	_
94-17	16797-16802	order	_
94-18	16803-16805	to	_
94-19	16806-16813	examine	_
94-20	16814-16817	the	_
94-21	16818-16826	relative	_
94-22	16827-16836	influence	_
94-23	16837-16839	of	_
94-24	16840-16844	that	_
94-25	16845-16853	variable	_
94-26	16854-16855	.	_

95-1	16856-16859	The	_
95-2	16860-16865	three	_
95-3	16866-16877	individuals	_
95-4	16878-16882	with	_
95-5	16883-16892	disorders	_
95-6	16893-16900	outside	_
95-7	16901-16903	of	_
95-8	16904-16907	the	_
95-9	16908-16915	classes	_
95-10	16916-16918	of	_
95-11	16919-16927	interest	_
95-12	16928-16932	were	_
95-13	16933-16941	combined	_
95-14	16942-16946	with	_
95-15	16947-16950	the	_
95-16	16951-16965	nonpsychiatric	_
95-17	16966-16974	controls	_
95-18	16975-16978	for	_
95-19	16979-16984	these	_
95-20	16985-16989	post	_
95-21	16990-16993	hoc	_
95-22	16994-17002	analyses	_
95-23	17003-17004	.	_

96-1	17005-17008	All	_
96-2	17009-17020	regressions	_
96-3	17021-17025	were	_
96-4	17026-17034	examined	_
96-5	17035-17038	for	_
96-6	17039-17056	multicollinearity	_
96-7	17057-17058	(	_
96-8	17059-17067	Variance	_
96-9	17068-17077	Inflation	_
96-10	17078-17084	Factor	_
96-11	17085-17086	>	_
96-12	17087-17088	4	_
96-13	17089-17091	or	_
96-14	17092-17101	Condition	_
96-15	17102-17107	Index	_
96-16	17108-17109	>	_
96-17	17110-17112	30	_
96-18	17113-17114	)	_
96-19	17115-17118	and	_
96-20	17119-17130	statistical	_
96-21	17131-17139	outliers	_
96-22	17140-17141	(	_
96-23	17142-17149	defined	_
96-24	17150-17152	by	_
96-25	17153-17164	combination	_
96-26	17165-17167	of	_
96-27	17168-17179	Studentized	_
96-28	17180-17188	residual	_
96-29	17189-17190	>	_
96-30	17191-17194	3.0	_
96-31	17195-17198	and	_
96-32	17199-17203	Cook	_
96-33	17204-17206	's	_
96-34	17207-17208	d	_
96-35	17209-17210	>	_
96-36	17211-17214	.03	_
96-37	17215-17216	)	_
96-38	17217-17218	.	_

97-1	17219-17222	Any	_
97-2	17223-17233	deviations	_
97-3	17234-17238	from	_
97-4	17239-17244	these	_
97-5	17245-17255	parameters	_
97-6	17256-17259	are	_
97-7	17260-17268	reported	_
97-8	17269-17271	in	_
97-9	17272-17275	the	_
97-10	17276-17283	results	_
97-11	17284-17285	.	_

98-1	17286-17290	This	_
98-2	17291-17293	is	_
98-3	17294-17295	a	_
98-4	17296-17299	PDF	_
98-5	17300-17304	file	_
98-6	17305-17307	of	_
98-7	17308-17310	an	_
98-8	17311-17319	unedited	_
98-9	17320-17330	manuscript	_
98-10	17331-17335	that	_
98-11	17336-17339	has	_
98-12	17340-17344	been	_
98-13	17345-17353	accepted	_
98-14	17354-17357	for	_
98-15	17358-17369	publication	_
98-16	17370-17371	.	_

99-1	17372-17374	As	_
99-2	17375-17376	a	_
99-3	17377-17384	service	_
99-4	17385-17387	to	_
99-5	17388-17391	our	_
99-6	17392-17401	customers	_
99-7	17402-17404	we	_
99-8	17405-17408	are	_
99-9	17409-17418	providing	_
99-10	17419-17423	this	_
99-11	17424-17429	early	_
99-12	17430-17437	version	_
99-13	17438-17440	of	_
99-14	17441-17444	the	_
99-15	17445-17455	manuscript	_
99-16	17456-17457	.	_

100-1	17458-17461	The	_
100-2	17462-17472	manuscript	_
100-3	17473-17477	will	_
100-4	17478-17485	undergo	_
100-5	17486-17497	copyediting	_
100-6	17498-17499	,	_
100-7	17500-17511	typesetting	_
100-8	17512-17513	,	_
100-9	17514-17517	and	_
100-10	17518-17524	review	_
100-11	17525-17527	of	_
100-12	17528-17531	the	_
100-13	17532-17541	resulting	_
100-14	17542-17547	proof	_
100-15	17548-17554	before	_
100-16	17555-17557	it	_
100-17	17558-17560	is	_
100-18	17561-17570	published	_
100-19	17571-17573	in	_
100-20	17574-17577	its	_
100-21	17578-17583	final	_
100-22	17584-17591	citable	_
100-23	17592-17596	form	_
100-24	17597-17598	.	_

101-1	17599-17605	Please	_
101-2	17606-17610	note	_
101-3	17611-17615	that	_
101-4	17616-17622	during	_
101-5	17623-17626	the	_
101-6	17627-17637	production	_
101-7	17638-17645	process	_
101-8	17646-17652	errors	_
101-9	17653-17656	may	_
101-10	17657-17659	be	_
101-11	17660-17670	discovered	_
101-12	17671-17676	which	_
101-13	17677-17682	could	_
101-14	17683-17689	affect	_
101-15	17690-17693	the	_
101-16	17694-17701	content	_
101-17	17702-17703	,	_
101-18	17704-17707	and	_
101-19	17708-17711	all	_
101-20	17712-17717	legal	_
101-21	17718-17729	disclaimers	_
101-22	17730-17734	that	_
101-23	17735-17740	apply	_
101-24	17741-17743	to	_
101-25	17744-17747	the	_
101-26	17748-17755	journal	_
101-27	17756-17763	pertain	_
101-28	17764-17765	.	_

102-1	17766-17776	Highlights	_
102-2	17777-17785	Delusion	_
102-3	17786-17794	severity	_
102-4	17795-17805	negatively	_
102-5	17806-17813	related	_
102-6	17814-17816	to	_
102-7	17817-17826	amplitude	_
102-8	17827-17829	of	_
102-9	17830-17832	P1	_
102-10	17833-17846	visual-evoked	_
102-11	17847-17856	potential	_
102-12	17857-17868	Constricted	_
102-13	17869-17875	affect	_
102-14	17876-17886	negatively	_
102-15	17887-17894	related	_
102-16	17895-17897	to	_
102-17	17898-17904	change	_
102-18	17905-17907	in	_
102-19	17908-17910	P1	_
102-20	17911-17920	amplitude	_
102-21	17921-17923	to	_
102-22	17924-17927	red	_
102-23	17928-17938	background	_
102-24	17939-17951	Participants	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
102-25	17952-17956	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
102-26	17957-17970	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
102-27	17971-17977	showed	_
102-28	17978-17985	reduced	_
102-29	17986-17988	P1	_
102-30	17989-17998	amplitude	_
102-31	17999-18007	compared	_
102-32	18008-18010	to	_
102-33	18011-18019	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder

